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GENERAL REMARKS 
 
1. 1H NMR spectra were recorded on Bruker avance II 400 MHz NMR 
spectrometer using TMS as an internal reference. 
 
2. Mass spectra were recorded on GC-MS QP-2010 spectrometer. 
 
3. IR spectra were recorded on Schimadzu FT-IR-8400 spectrometer. 
 
4. Elemental analysis was carried out on Vario EL III Carlo Erba 1108. 
 
5. Thin layer chromatography was performed on Silica Gel (Merck 60 F254). 
 
6. The chemicals used for the synthesis of compounds were purchased from 
Spectrochem, Merck and Ranchem. 
 
7. Melting Points were taken in open capillary and are uncorrected. 
 
8. Microwave assisted reaction were carried out in QPro-M microwave 
synthesizer. 
 
9. All the structures are drawn according to ACS Document 1996 style. 
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Synopsis 
 
“STUDIES ON SOME HETEROCYCLIC COMPOUNDS  
OF MEDICINAL INTEREST” 
A comprehensive summary of the work incorporated in the thesis with 
the title “STUDIES ON SOME HETEROCYCLIC COMPOUNDS OF 
MEDICINAL INTEREST” has been described as under. 
 
CHAPTER- I  GENERAL INTRODUCTION 
CHAPTER - II STUDIES ON CYANOPYRIDONE 
CHAPTER - III STUDIES ON PYRIDOPYRIMIDINE 
CHAPTER - IV  STUDIES ON BENZOPYRAN 
 
CHAPTER - I GENERAL INTRODUCTION 
Nowadays, the entire pharmaceutical industry is faced with the 
challenge of increasing productivity and innovation. The major hurdles are the 
increasing costs of research and development (R & D) and a simultaneous 
stagnating number of new chemical entities (NCEs). 
Part-1 deals with a brief introduction for the pressing need of New 
Chemical Entity (NCE) for pharmaceutical industry. It also describes 
importance of bicyclic aromatic heterocyclic in drug discovery. The concept of 
“privileged structures” is also explained in brief. Part-1 also described aims 
and objectives of the proposed synthetic research work. 
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CHAPTER - II STUDIES ON CYANOPYRIDONES 
The pyridine skeleton is of great importance to chemists as well as to 
biologists as it is found in a large variety of naturally occurring compounds 
and also in clinically useful molecules having diverse biological activities. In 
association with those, Pyridone and their derivatives play an essential role in 
several biological processes and have considerable chemical and 
pharmacological importance. 2-Pyridones represent a unique class of 
pharmacophore, which are observed in various therapeutic agents and 
antibiotics. 
 
 Cyanopyridone of type (I) has been synthesized by the condensation of 
different arylidene and malononitrial in presence of catalytic amount 
pipyridine.   
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 CHAPTER - III STUDIES ON PYRIDOPYRIMIDINE 
 The synthesis of pyrido pyrimidine and their derivative is of high interest 
in organic chemistry, because some are possessing biological and 
pharmacological activities. The pyrido pyrimidine functionality has also been 
used for the development of biologically interesting molecules. Earlier 
reported procedures for the synthesis of pyrido pyrimidines typically involved 
a multistep-approach. Pyrido pyrimidines were reported to be used as a 
cytotoxic agents, mycobacterium dihydrofolate reductace, anti-tumor, antiviral 
and antimicrobial activities. 
 
 Pyridopyrimidine of type-(II) has been synthesized by the condensation  
of cyanopyridone type-(I) with glacial acetic acid in the presence of catalytic 
amount of conc. Sulphuric acid undergo microwave irradiation.   
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CHAPTER - IV STUDIES ON BENZOPYRAN 
In recent years, the synthesis of benzopyran derivatives has attracted 
great interest. Since the discovery of cromakalim as a typical ATP-sensitive 
potassium channel opener (PCO), a large number of benzopyran derivatives 
have been synthesized and demonstrated to possess potent relaxant activity 
on blood vessels, cardiac muscle, and other smooth muscles.These agents 
may find use in the treatment of a variety of diseases such as hypertension, 
asthma, ischemia, and urinary incontinence. The pyran pharmacophore is an 
important core structure of many natural products showing antibacterial, 
antitumor, antiallergic, antibiotic, hypolipidemic and immunomodulating 
activities. When the hydrogen atom of pyran ring is substituted by amino or 
cyano, they become synthons of some natural products. 
 
 Benzopyran of type (III) has been synthesized by the condensation of 
5-methyl resorcinol with different substituted arylidene in presence of 
anhydrous potassium carbonate. 
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CHARACTERISATION 
The constitution of all above products has been supported by 
elemental analysis and spectral studies like IR, 1HNMR and mass 
spectroscopy. The purity of the newly synthesized compounds was checked 
by TLC. 
 
IN VITRO STUDY ON MULTIPLE BIOLOGICAL ACTIVITIES 
All the compounds have been evaluated for their antibacterial activity 
towards Gram +ve and Gram -ve bacterial strains and antifungal activity 
towards fungal strain at different concentration. The biological activities of the 
synthesized compounds have been compared with standard drugs. 
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Chapter 1 
General Introduction 
  
 
 
1.1  Heterocycles in Medicinal Chemistry 
Nowadays, Research in the field of pharmaceutical has its most 
important task in the Development of new and better drugs and their 
successful introduction into clinical practice.  The entire pharmaceutical 
industry is faced with the challenge of increasing productivity and innovation. 
The major hurdles are the increasing costs of research and development and 
a simultaneous stagnating number of new chemical entities (NCEs).  
 Medicinal chemistry as a scientific discipline has introduced several 
new techniques over the last few years in order to speed up the drug 
discovery process, such as combinatorial chemistry, microwave-assisted 
organic synthesis (MAOS) and high-throughput purification [1-3]. Despite this 
steady increase in R & D, the number of NCEs reaching the market has 
actually decreased dramatically. 
 In order to start a new drug discovery project and to find biologically 
active compounds, different options are available. Hits can be obtained via a 
virtual screening approach or can be copied from scientific or patent literature. 
Very often, drug discovery projects start with a high-throughput screening 
campaign of commercially available compound libraries against the target of 
interest. It became clear in recent years that combinatorial libraries are not 
diverse enough. As the main interest of the laboratory of medicinal chemistry 
lays in the synthesis and biological evaluation of aromatic heterocycles, we 
performed a literature survey of commercially available combinatorial libraries. 
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This search revealed that the number of available heterocycles is mainly 
limited to well-known nitrogen containing compounds, such as quinazolines 
(1), indoles (2) and benzimidazole (3). 
N
N N
H
N
H
N
(1) Quinazoline (2) Indole (3) Benzimidazole
N
H
N
O
(4) 1,4-Benzodiazepine-2-one
O O
(5) Coumarine
N
N
(6) Quinoxaline
O
(7) Benzofuran
S
(8) Benzothiophene
Examples of privileged structures
 
These structural classes are considered to be privileged structures. 
The concept of “privileged structures” was first proposed by Evans et al. to 
describe selected structural types that bind to multiple, unrelated classes of 
protein receptors and enzymes as high affinity ligands [4]. These privileged 
structures are typically rigid, polycyclic heteroatom systems capable of 
orienting the various substituents in a well-defined three-dimensional space. 
Well-known examples of privileged substructures include benzodiazepines 
(4), coumarins (5), quinoxalines (6), benzofurans (7) and benzothiophenes (8) 
[5]. In order to improve the hit rate in HTS campaigns, privileged structures 
provide an ideal source of lead compounds. A single library based upon 
privileged substructures can lead to active compounds in variety of biological 
assays. Several research groups have utilized these structures in such a 
manner. For example, Nicolau and co-workers constructed a library based on 
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the benzopyran (9) privileged scaffold [6], whereas Schultz and co-workers 
made use of the purine (10) scaffold [7]. 
 
 
The basis of understanding in the medicinal chemistry lies in an 
awareness of the relationships between the chemistry of a particular 
compound or group of compounds and their interactions with the body, which 
is known as structure activity relationship (SAR), and the mechanism by which 
the compound influences the biological system, which is known as its mode of 
action.  
 
We must always continue to search for drugs which exhibit clear 
advantages over the already existing respective drugs. Such advantages may 
be:  
 
[1] A qualitative or quantitative improvement in activity,  
[2] A partial or total absence of undesirable side effects, 
[3] A lower toxicity, 
[4] More nutritive value,  
[5] Improved stability and  
[6] A decrease in production cost. 
   
Any drug must ideally have a broad spectrum of activity, with a rapid 
bactericidal action. Some bacteria produce enzymes that can inactivate or 
modify antibiotics action. Some bacteria produce enzymes that can inactivate 
or modify antibiotics, and insusceptibility of a drug to such degradation or 
modification could result in its playing an important part in therapy. Likewise, 
some bacteria possess an outer membrane that acts as a permeability barrier 
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to the entry of some, but not all, antibiotics. Drugs that can readily penetrate 
this barrier might again be expected to be of possible clinical importance. 
Dynamic development and automation of medicinal chemistry 
approaches lead to an increased demand of compounds for biological 
evaluation.  
The search for novel therapeutics is based on four major strategies: 
[1] Screening of natural and synthetic compound libraries - mixture of  
compounds 
[2] Screening of random compound collections, combinatorial chemistry 
[3] Focused compound collections - literature based drug design 
[4] Computational drug design 
 
As an early approach to produce numerous compounds and complex 
libraries in microgram quantities, split-and-mix synthesis in combination with 
solid phase organic chemistry was used. [8-9] Limited success from biological 
screening with regard to false-positives and problems with identification of 
active ingredients in the screened mixtures, due to insufficient purification and 
quality control methods, was the major drawback of the strategy. The high 
expectations placed upon early combinatorial libraries remained therefore 
unfulfilled. 
 
The mentioned problems were avoided by high- throughput screening 
of random compound collections. The approach is based on the investigation 
of a series of single, characterized compounds with defined purity criteria. 
When no specific structure or substructure is obligatory as a starting point the 
approach initially requires a large number of diverse compounds in order to 
increase the chance to identify a compound of the novel biological target or an 
alternative lead structure for a known target. In addition to the collection sizes 
the probability to find a hit molecule might be further increased by using 
structural motifs that are appearing frequently in potent drugs and drug 
candidates or by selecting scaffolds which are straight forward to prepare and 
allow the synthesis of highly diverse compounds. [10-11] 
Further improvement in drug development was reached by generation 
of focused collections. The main task of this approach is not necessarily to 
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provide large numbers of compounds but rather to improve hit rates by 
exploring molecular space. The term focused is not clearly defined. One 
category is target-family oriented collections that consist of compounds 
specifically designed to target certain protein families. Such sets of 
compounds require up to 50,000 molecules. More specific collections address 
a certain target protein and therefore the number of compounds may 
decrease to 2,000, designed around a specific scaffold class. In a hit-to-lead 
or lead-optimization the compound number is smaller, around 20-500. 
 
Careful and smart design of libraries is crucial for the success in 
respect of physicochemical properties of molecules. The design principles can 
vary depending on the purpose of a collection. For a hit finding or target-
oriented collection a basic tool is Lipinski’s rule of five. Advances in molecular 
biology, protein engineering, and biophysical techniques are providing 
structural information about therapeutic targets, which are of great importance 
for creation of active candidates. Incorporation of key structures and 
recognition elements for receptor binding that is relevant to the particular 
biological target is often essential. However, the prediction of the influence of 
the specific lead modification is highly limited, due to the changes of ligands 
binding affinity or certain biological effects caused by nonspecific inhibition 
phenomena. Therefore often structure-based discovery strategies still require 
the preparation of many ‘designed’ compounds. [12] 
 
To increase the efficiency of the drug discovery process efforts are 
focused on computer based techniques that assist drug development. 
Software programs are used for the creation of the corresponding virtual 
compound library, and the selection of the compounds to be synthesized and 
screened based on drug-likeness. There are enzyme pocket-homology 
models available for enzymes, which are used to assess proposals for new 
scaffolds taking into consideration their fit into binding pockets. Additionally 
more sophisticated tools, such as docking, pharmacophore or QSAR 
(Quantitative Structure-Activity Relationship)-based models might be used in 
combination with or instead of other mentioned approaches in more advanced 
stages of lead optimization.  
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Experimental methods which promise to shorten the drug discovery 
and development time or its cost are eagerly taken up. One of the useful 
techniques is combinatorial chemistry that allows the preparation of a large 
number of structurally related compounds either as mixtures in the same 
reaction vessel or individually by parallel synthesis. Combinatorial collections 
have been prepared using both solution chemistry and solid phase synthesis 
or by the combination of both. The great power of the high-throughput 
chemistry techniques is clearly seen when they are integrated with other tools 
used in drug discovery. [13-17] 
 
An extensive advance and success enhancement in medicinal 
chemistry and drug discovery is nowadays achieved by combining the speed 
power of combinatorial chemistry with the precision of structure-based design 
and potential of computational methods. 
 
During the period of 1940 to 1960 a large number of important drugs 
have been introduced and this period is regarded as "Golden Period" of new 
drug discovery. These are some of the specific examples representing new 
therapeutics. 
 
NAME OF DRUGS    YEAR  USAGES 
Sulfa drugs     1933   First antibacterial drug 
Penicillin     1940   Antibiotics 
Chloroquine     1945   Antimalarial 
Methyldopa     1950  Antidiabetic 
Chlorthiazide    1957  Diuretic 
Adrenergic betablockers   1958   Coronary Vasodilatory 
Semi synthetic penicillins   1960   Antibacterial 
Trimethoprim    1965   Antimicrobial 
Disodium chromoglycoate   1967   Antiallergic 
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During the past decade, the threat of antimicrobial resistance has 
become increasingly real and its global dimensions have been increasingly 
recognized. Antimicrobial resistance is defined as a property of bacteria that 
confers the capacity to inactivate or exclude antibiotics, or a mechanism that 
blocks the inhibitory or killing effects of antibiotics, leading to survival despite 
exposure to antimicrobials.  
 
Some bacteria become multi-resistant, i.e., resistant to different groups 
of antibiotics. Increasing reports of outbreaks of antimicrobial resistant 
bacteria, such as hospital outbreaks of vancomycin resistant enterococci, 
community outbreaks of antimicrobial resistant. Streptococcus pneumoniae 
and human and animal outbreaks of multi-resistant. Salmonella Typhimurium 
definitive type 104, have heightened the concerns of the international public - 
and animal-health communities, medical and veterinary clinicians and the 
general public.  
 
Another reason for increased concern is the slowing of research and 
development of new antimicrobials due to the cost and time to develop new 
drugs as well as a focus by pharmaceutical companies on developing 
products for non-infectious disease. 
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1.2 Nomenclature of the Fused Ring System 
 
As the following chapters deal with the synthesis of bicyclic and tricyclic 
fused ring systems, its nomenclature is herewith shortly reviewed. The 
nomenclature follows the following rules: 
[1] The individual components are named without any application of fused 
ring system. 
[2] The parent component is represented in the fusion name by citing it 
last in the name. The parent component is the one with highest priority 
according to the following criteria: 
(a)  A heterocyclic component containing the heteroatom occurring 
earliest in the order: N, F, Cl, Br, I, O, S, Se, Te, P, As, Sb, Bi, 
Si, Ge, Sn, Pb, B, Hg. 
(b)  A component containing the larger ring 
(c)  A component containing the greater number of heteroatom. 
(d)  A component containing the greater variety of heteroatom. 
[3] The attached component is then added as a prefix to the parent 
component. In the name of the prefix, the terminal 'e' is changed to 'o'. 
[4] The bonds of the parent component are indicated by a, b, c…starting 
with the bond normally occupying the 1, 2 positions. The atoms of the 
attached component are numbered as usual, following the order of 
numbers in the original heterocycles. 
[5] The numbering of the final condensed heterocycles is carried out 
independently, starting at an atom adjacent to a bridged-head atom, 
whereby heteroatom receive the smallest possible number. 
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1.3 Aims and Objectives 
 
In the pharmaceutical field, there has always been and will continue to 
be a need for new and novel chemical entities with diverse biological 
activities. Our efforts are focused on the introduction of chemical diversity in 
the molecular frame work in order to synthesizing pharmacologically 
interesting compounds of widely different composition. 
 
During the course of research work, several entities have been 
designed, generated and characterized using spectral studies. The details are 
as under. 
 
[1] To generate several derivatives like cyclooctano pyridine, amino 
pyridine, pyrido pyrimidine, pyrazolo pyridine, pyrido thiopyrimidine 
bearing with amide linkage. 
[2] To check the purity of all compounds using thin layer chromatography. 
[3] To characterize these products for structure elucidation using 
spectroscopic techniques like IR, PMR and Mass spectral studies. 
[4] To evaluate these new products for better drug potential against 
different strains of bacteria and fungi. 
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Chapter 2 
Synthesis and Biological Evaluation 
of Cyanopyridones 
 
2.1 Introduction 
The pyridine skeleton is of great importance to chemists as well as to 
biologists as it is found in a large variety of naturally occurring compounds 
and also in clinically useful molecules having diverse biological activities. The 
pyridine ring systems have emerged as integral backbones of over 7000 
existing drugs [1, 2]. The pyridine ring is also an integral part of anticancer and 
anti-inflammatory agents [3]. 
In association with those, Pyridone and their derivatives play an 
essential role in several biological processes and have considerable chemical 
and pharmacological importance [4-6]. 2-Pyridones represent a unique class of 
pharmacophore, which are observed in various therapeutic agents [7] and 
antibiotics [8]. These heterocycles attracted attention because of their 
applications as bioactive compounds for example as a promising class of HIV-
1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) [9],
 
as antibacterial 
[10],
 
antifungal [11], sedative [12]
 
and cardiotonic agents [13].
 
Moreover, such 
derivatives have recently become important due to their structural similarity to 
nucleosides [14].
 
Also, 2-pyridones were used as ligands for the late 3d-metals 
[15].
 
 
They are also versatile precursors for the construction of complex 
natural products [16] pyridines [17] and larger Pyridone systems such as those 
found in the nitro guanidine insecticide Imidacloprid [18] and subtype selective 
GABAA receptor agonists [19]. Consequently, methodologies for the 
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preparation of pyridones have attracted much attention from both industry and 
academia. 
3-Cyano-2-Pyridones are much interest in the anticancer activity of 
these compounds owing to different types of biological targets they might 
interfere with for this effect to occur e.g. PDE3, PIM1 Kinase, and Survivin 
protein. The 3-cyanopyridin-2-one nucleus is the structural basis of the 
alkaloid ricinine (2), the first known alkaloid containing a cyano-group. 
 
Milrinone (1) is a 3-cyano-2-oxopyridine derivative that has been 
introduced to the clinic for the treatment of congestive heart failure. Its 
mechanism of action involves PDE3 inhibition, leading to high levels of cAMP 
and consequent isotropic effect. Recent studies showed that PDE3, PDE4 
and PDE5 are over expressed in cancerous cells compared with normal cells. 
In addition, cross inhibition of PDE3 together with other PDEs may lead to 
inhibition of tumor cell growth and angiogenesis [20-24]. The inhibition of PDE3 
was able to inhibit the growth and proliferation of the squamous cell 
carcinoma cell line HeLa, and in HSG cells and further studies revealed that 
the pyridone derivative, cilostamide- a selective PDE3 inhibitor- has 
synergism action to the anti-apoptotic action of PDE4 inhibitors in leukemia 
cells [23-25]. 
Cheney et al. reported 4,6-diaryl-2-oxo-1,2-dihydropyridine-3-
carbonitriles (3), as inhibitors of the oncogenic serine/threonine kinas PIM-1, 
which plays a role in cancer cell survival, differentiation and proliferation. PIM-
1 kinas have been shown to be over expressed in a variety of cancer cell lines 
[26]. 
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Wendt et al. showed that several compounds with the same general 
formula as above but with higher lipophilic properties (4) can inhibit surviving 
which is a member of the inhibitor of apoptosis family (IAP) [27]. The level of 
expression of surviving in tumor cells is often associated with poor prognosis 
and shorter patient survival rates. Surviving is highly expressed in most 
human tumors and fetal tissue but undetectable in most terminally 
differentiated adult tissues. This fact therefore makes surviving an ideal target 
for cancer therapy [28, 29]. 
 
           The thienopyridone agonist (5) is showed modest AMPK activity. 
AMPK (adenosine monophosphate-activated protein kinase), a heterotrimeric 
serine/ threonine kinase, is well established as a key sensor and regulator of 
intracellular and whole-body energy metabolism [30]. Activation of AMPK alters 
carbohydrate and lipid metabolism to increase fatty acid oxidation and 
glucose uptake and decrease fatty acid and cholesterol synthesis. Through its 
central role in the regulation of glucose and lipid metabolism, AMPK is 
emerging as an attractive molecular target for the treatment of diabetes, 
metabolic syndrome, and obesity [31, 32]. 
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2. 2  Reported Synthetic Strategies 
2.2.1  One-pot multi-component synthesis of 3-cyano-2-pyridinones 
Beheshtia et al. developing new selective and environmental friendly 
methodologies for the preparation of fine chemicals, they performed the 
synthesis of 4-alkyl(aryl)-6-aryl-3-cyano-2(1H)-pyridinones and their 2-imino 
isosteres [33-36] through one-pot multi-component reaction of 3,4-
dimethoxyacetophenone, malonitrile or ethyl cyanoacetate, an aldehyde and 
ammonium acetate in the presence of K2CO3 (Scheme 2.1). 
This reaction was carried out in various solvents such as water, DMF, 
chloroform, ethanol, CH2Cl2 and toluene. The best results in terms of yield 
and time were obtained in ethanol. By carrying out reactions with different 
amounts of ammonium acetate, it has been found that 8 mmol of the 
ammonium acetate furnished the maximum yield for 1 mmol of the reactants. 
When ethyl cyanoacetate was used instead of malononitrile, the 
corresponding 2-pyridone was obtained in good yield. 
 
Also, they have used Et3N instead of K2CO3 in these reactions, but 
K2CO3 affords better yields. In addition, the time required for completion of the 
reaction was found to be less with K2CO3. 
The one-pot reaction of 2-cyanoacetohydrazide (Scheme 2.2) with 
aldehyde and an activated nitrile in ethanol containing a catalytic amount of 
piperidine yielded pyridine-2-one derivative [37-39]. 
Chapter 2                                                                                  Cyanopyridone 
 
  Page 20 
 
O NH
NC
NH2
+
NH
R
NC
O
NH2
X
N
R
NC
O
NH2
NH2
X
Scheme 2.2
R CHO
X
CN
EtOH
piperidine CN
R = H, Me, aryl
X = CN, COPh, CO2Ph
 
2.2.2 From α, β-unsaturated reagents 
Condensation of ethyl cyanoacetate with α,β-unsaturated ketones in 
presence of excess ammonium acetate afforded 3-cyanopyridin-2-ones [40-43] 
(Scheme 2.3). Also, a green chemistry approach describing reaction of α,β-
unsaturated ketones with ethyl cyanoacetate using samarium iodide as 
catalyst has been reported recently [44]. 
   
Barat reported first that condensation of cyanoacetamide with α,β-
unsaturated ketones also affords 3-cyanopyridin-2-ones. Number of reports 
following this approach have been reported till date [45-47] (Scheme 2.4). 
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Chase et al. have synthesized 6-amino-5-phenyl-3-cyanopyridin-2-one 
by the reaction of 3-isobutoxy-2-phenylacrylonitrile with cyanoacetamide [48] 
(Scheme 2.5).  
 
Reaction of ethyl-(2,3,4-trimethoxybenzoyl)-pyruvate with 
cyanoacetamide in ethanol in presence of  piperidine gave 4-carbehtoxy-6-
(2,3,4-trimethoxybenzyl)-3-cyanopyridin-2-one [49]  (Scheme 2.6). 
 
Alnajjar et al. [50] reported the conversions of 2-cyano-5-
(dimethylamino)-5-phenylpenta-2,4-dienamides into nicotinic acid derivatives 
by boiling in EtOH/HCl. But, When 2-cyano-5-(dimethylamino)-5-phenylpenta-
2,4-dienamides are heated under reflux in AcOH, nicotinic nitrile derivatives 
are obtained (Scheme 2.7). 
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The condensation of an enone or enal with cyanoacetamide derivatives 
and t- BuOK furnishes either 3-cyano-2-pyridones or 3-unsubstituted-2-
pyridones (Scheme 2.8), depending on whether the reaction is carried out in 
the presence or in the absence of O2. In the first case, in situ oxidation of 
Michael-type intermediates takes place; in the second case, a "decyanidative 
aromatization" of such intermediates occurs [51, 52]. 
R1 O
R2
R3
+
CONH2
CN DMSO
excess O2
no O2
H
N OR1
R2
R3
CN
H
N OR1
R2
R3Scheme 2.8
t-BuOK
 
The synthesis of 2,6-piperidindione derivatives (Scheme 2.9) was 
achieved by the Michael addition of dialkylmalonates to benzylidene 
cyanoacetamide derivative. Here benzylidene cyanoacetamide derivative 
were obtained by reaction of cyano-acetamide with certain aromatic 
aldehydes according to the reported procedure [53]. 
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Enaminonitrile reacted with an equimolar amount of a-cinnamonitriles 
to provide pyridine and pyridinone derivatives [54], respectively. Formation of 
pyridine and pyridinone derivatives is assumed to proceed via an acyclic 
intermediate form followed by intramolecular cyclization and spontaneous 
autooxidation under the reaction conditions in the case of pyridine derivatives 
and elimination of ethanol in the case of pyridone derivatives (Scheme 2.10). 
Here, the enaminonitrile can be readily prepared by reaction of 
acetonitrile with 4-cyanopyridine in the presence of potassium-t-butoxide [55]. 
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Mathews et al. [56] attempted the reaction of 2-aroyl-3,3-
bis(alkylsulfanyl) acrylaldehydes with cyanoacetamide in the presence of 
ammonium acetate/acetic acid at 80 °C, it afforded only the Knoevenagel 
condensation adduct, 4-aroyl-2-cyano-5,5-bis-(methylsulfanyl)-2,4-pentadien-
amides and no 2-pyridone was formed. As the condensation product has the 
scope for cyclization to produce 2-pyridones by the elimination of an 
alkylsulfanyl group, they tried the thermal cyclization of the condensation 
products by heating in xylene at 130 °C (Scheme 2.11).  
 
Condensation of ketone with dimethylformamide dimethylacetal 
afforded vinylogous amide, which in turn reacted with cyanoacetamide under 
basic conditions to generate the 5,6-diaryl-3-cyano-2-pyridones (Scheme 
2.12) [57]. 
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The reaction of (E)-1-(β-D-glucopyranosyl)-4-(aryl)but-3-en-2-ones and 
cyanoacetamide was carried out (Scheme 2.13) with t-BuOK in DMSO under 
N2 atmosphere at ambient temperature to give the respective 3-cyano-4-
phenyl-6-[(β-D-glucopyranosyl)methyl]pyridones [58]. The reaction mixture was 
brought under the influence of an O2 atmosphere to carry out oxidative 
aromatization. 
 Here, the starting butenonyl C-glycosides were prepared from 
commercially available D-glucose following earlier reported protocols [59-62]. 
 
2-alkoxy-3-cyanopyridines is achieved by the reaction of chalcones 
with malononitrile in corresponding sodium alkoxide [63-66] (Scheme 2.14).  
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Another frequently used approach for the synthesis of 2-alkoxy-3-
cyano-pyridines is the O-alkylation of 3-cyanopyridin-2-ones by the reaction 
with appropriate alkyl/aryl halide [67, 68] (Scheme 2.15).  
 
2.2.3  From 1,3-dicarbonyl reagents 
Literature survey revealed many reports on synthesis of 3-
cyanopyridin-2-one and 3-cyanopyridin-2-thione by reaction of 1,3-dicarbonyl 
compounds with cyanoacetamide [69-72] and cyanothioacetamide [73-75] 
respectively (Scheme  2.16). 
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The pyridone derivatives were also obtained from a cyclo-condensation 
reaction in one step (Scheme 2.17) [28]. Reaction of commercially available 
diketone with cyanoacetamide, in the presence of DBU in toluene at 90 °C for 
16 h, readily afforded the title compounds. 
 
5-Substituted-4-methyl-3-cyano-6-hydroxy-2-pyridones were 
synthesized from cyanoacetamide and the corresponding alkyl ethyl 
acetoacetate in methanol in the presence of potassium hydroxide at 60 ºC. 
Cyclization of cyanoacetamide with an alkyl ethyl acetoacetate belongs to a 3-
2 type of condensation where the pyridine nucleus is formed (Scheme 2.18) 
[76]. 
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2.2.4  Miscellaneous 
Literature survey also revealed a few ring transformation reactions of 4-
amino-1H-1,5-benzodiazepine-3-carbonitrile [77] and substituted uracil [78] 
yielding 3-cyano-pyridones.  
Nohara et al. have reported that heating 2-cyano-3-(6-ethyl-4-oxo-4H-
1-benzopyran-3-yl) acrylamide in pyridine yields 3-cyano-5-(5-ethyl-2-
hydroxy-benzoyl)-2(1H)-pyridones [79] (Scheme 2.19). 
 
Treatment of the ketones with dimethylformamide-dimethylacetal 
(DMF-DMA) gave the corresponding 3-dimethylaminopropen-2-ones, and 
generally without purification, these were condensed with 2-cyanoacetamide 
under basic condition give the 3-cyano-2-pyridones, reported by Collins et al. 
[12] (Scheme 2.20). 
 
The 2-(2-cyano-acetylamino)-4-aryl-thiophene-3-carboxylic acid ethyl 
esters were treated with sodium hydride in tetrahydrofuran at temperatures 
ranging from 25 to 80 °C to provide the thienopyridone compounds [35] 
(Scheme 2.21). 
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2.2.5  Synthesis of N-substituted-cyanopyridones 
Melikyan et al. have reported synthesis of novel N-substituted-3-
cyanopyridin-2-ones from ylidenecyanoacetic acid ethyl esters in two steps [80] 
(Scheme 2.22). 
 
On heating 2-cyanoacetohydrazide and arylidene of ethyl cyanoacetate 
in ethanol containing triethyl amine under reflux afforded diaminopyridine 
derivative rather than aminopyridine derivative [81, 82] (Scheme 2.23). 
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Martin and coworkers reinvestigated the cyclocondensation of 2-
cyanoaceto-hydrazide with (4-methoxybenzylidene)malononitrile (Scheme 
2.24). They have found that prolonged heating lead only to the formation of 
1,6-diamino-4-(4-methoxy-phenyl) -3,5-dicyano-2-pyridone [83]. 
 
Substituted N-benzoylaminopyridone was prepared by 
cyclocondensation of N-benzoylcyano-acetohydrazide with ethyl acetoacetate 
in presence of sodium methoxide [84] (Scheme 2.25). 
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The reaction of N-cyanoacetylhydrazone of epiandrosterone with 
malononitrile in ethanol in the presence of a catalytic amount of piperidine 
afforded pyridine-2-one derivative [85] (Scheme 2.26). 
 
Shams et al. [86] reported the reaction of the benzylidene derivative with 
methylene carbonitrile reagents (XCH2CN; X = CN, X = CO2Et) afforded the 
respective pyridone derivatives (Scheme 2.4). The reaction took place via β-
attack on the benzylidene moiety followed by 1,6-intramolecular dipolar 
cyclization with concomitant aromatization. Further confirmation of the 
reaction products was achieved through an alternative synthetic route 
involving treatment of the starting compound cyano acetamide with 
benzylidene carbonitrile reagents (PhCH=C(CN)X; X = CN; X = COOEt) to 
afford the same pyridone derivatives with better yields (80%, 86%) than in 
their formation by the reaction of benzylidene derivative and either 
malononitrile (75% yield) or ethyl cyanoacetate (73% yield) (Scheme 2.27). 
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Reactions of N-substituted cyanoacetamides with diethyl-2-
(ethoxymethylene) malonate (DEEMM) [87] in EtOH in the presence of EtONa 
at room temperature resulted in the isolation of diaryl derivatives as major 
products (Method A) instead of the expected ethyl carboxylates (Scheme 
2.28). 
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Thus, to examine a possible alternative synthetic route to such 
molecules, and also to model one of the possible reaction stages of their 
formation from cyanoacetamides and DEEMM (Scheme 2.28), 
ethoxymethylene derivatives were used (Scheme 2.29). Thus, their reaction 
with cyanoacetamides under the same conditions resulted in formation of the 
desired derivatives (Method B) [88]. 
N
H
O
CN
N N
H
O
NH2N
CN
O
R HC(OEt)3
R
R = H, 4-Me, 2-OMe, 2-Et, 3-Me, 4-F
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OEt
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El-Rady et al. [89] reported the synthesis of 5-cyano-3-phenylmethylene-
pyridines by the condensation of 2-cyano-3-phenyl-N-p-tolylacrylamide with 
cyanoacetamide or cyanothioacet-amide or cyanoacetic acid hydrazide in 
ethanolic solution at reflux in the presence of drops of piperidine (Scheme 
2.30). The isomers 3,5-dicyano-2,3-dihydropyridines which have the same 
m/e are ruled out based mainly on the spectral analysis. 
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2.2.6  Enzymatic synthesis of 3-cyano-2-pyridones 
Lipases, including Candida rugosa, formerly C. cylindracea, were used 
to synthesize the substituted 3-cyano-2-pyridones [90-93]. Unlike conventional 
syntheses that require heating in the presence of various catalysts and 
usually polar organic solvents, enzymatic synthesis was achieved under mild 
reaction conditions. Under such conditions, various 4,6-disubstituted-3-cyano-
2-pyridones were obtained, including aryl-substituted-3-cyano-2-pyridones 
(Scheme 2.31). 
 
Prlainovic et al. [94] studies the kinetics of the enzyme-catalyzed 
synthesis of 4,6-disubstituted-3-cyano-2-pyridones showed that the behavior 
of the lipase used as the catalyst in the synthesis of 4,6-dimethyl-3-cyano-2-
pyridone is more complicated than that of chemical catalysts [92]. 
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2.2.7  Cyanopyridones via ultrasound and microwave irradiation 
Al-Zaydi [95] reported the synthesis of cyanopyridones via heating 
cyano-acetamide derivative with ethyl acetoacetate in absence of solvent 
under reflux conventionally or ultrasound irradiation or in a microwave oven. 
They have prepared Several cyanoacetamides via treatment of 
ethylcyano-acetate with primary amines either at room temperature for a 
longer time or via irradiation with microwave for 1 min. at 100 W or with 
ultrasound for 2 min. at 40 ºC. Then cyanoacetamides was reacted with an 
ethyl acetoacetate also either via a longer time using reflux of neat reagents 
and by a short time microwave or by ultrasound to afford cyanopyridones 
(Scheme 2.32). 
 
Also, Gorobets et al. [96] develop a rapid microwave assisted protocol 
for the solution phase synthesis of highly substituted 2-pyridone derivatives 
(Scheme 2.33). They introduce general microwave-assisted [97] three 
component one-pot synthesis of highly substituted 2-pyridones, utilizing CH-
acidic substrates, dimethylformamide dimethylacetal (DMF-DMA) and diverse 
methylene active nitriles [98]. 
The substituted 2-pyridone derivatives were obtained when a mixture 
of enamine, malononitrile and catalytic amounts of piperidine in i-PrOH was 
irradiated at 100 °C for 5 min. 
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2.2.8  Synthesis of 3-cyano-2-pyridones by using vinamidinium salts 
5-Aryl-3-cyano-2-pyridones have been prepared by the cyclization of 
cyanoacetamide condensated with 2-aryl-3-dimethylamino-2-propenals. As 
shown in Scheme 2.34, the 2-arylvinamidinium salts were condensed with 
cyanoacetamide in refluxing methanol that contained sodium methoxide to 
give the desired 5-aryl-3-cyano-2-pyridones [99]. The vinamidinium salts were 
prepared by the standard Vilsmeier-Haack reaction from the appropriate aryl 
acetic acid. 
 
2.2.9  Synthesis of azo-cyanopyridones 
Azo pyridines were synthesized by the diazotization-coupling reaction, 
as shown in Scheme 2.35. In this procedure acetylacetone was coupled with 
diazotised substituted aniline to give an intermediate (3-(substituted-
phenylazo)-2, 4-pentanedione), which was then cyclized with cyanoacetamide 
to yield an azo-pyridones [100]. 
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2.3  Present Work 
The chemistry of pyridine and its derivatives has been studied for over 
a century due to their diverse biological activities. 3-cyano-2-pyridone 
derivatives draw a special attention for their wide spectrum biological activities 
along with their importance and utility as intermediates in preparing variety of 
heterocyclic compounds.  
Keeping in mind, various biomedical applications and with a view to 
further assess the pharmacological profile of this class of compounds, four 
novel series of 3-cyano-2-pyridones (KMK-101 to KMK-140) have been 
synthesized. 
The synthesis of 3-cyano-2-pyridones was achieved by the reaction of 
an appropriate aromatic aldehydes, 2-cyano-N-(substituted)acetamides and 
malononitrile by using methanol as a solvent and piperidine as a catalyst. 2-
cyano-N-(substituted) acetamides were prepared by the reaction of 
substituted anilines with ethyl cyanoacetate[101]. The products were 
characterized by FT-IR, mass, 1H NMR spectroscopy and elemental analyses. 
The newly synthesized compounds were subjected to biological activities viz., 
antimicrobial. 
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2.4  Reaction Scheme 
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2.4.1 Physical Data Table 
Code R1 R2 M.F. 
M.W. 
(gm/
mole) 
M.P. 
(0C) 
% of 
yield 
 
KMK-101 2-Cl-5-Cl-phenyl H C19H10Cl2N4O 380 272-274 71 
KMK-102 2-Cl-5-Cl-phenyl 4-OCH3 C20H12Cl2N4O2 410 280-284 66 
KMK-103 2-Cl-5-Cl-phenyl 2-OCH3 C20H12Cl2N4O2 410 254-258 75 
KMK-104 2-Cl-5-Cl-phenyl 4-NO2 C19H9Cl2N5O3 425 245-250 74 
KMK-105 2-Cl-5-Cl-phenyl 2-NO2 C19H9Cl2N5O3 425 234-236 78 
KMK-106 2-Cl-5-Cl-phenyl 4-CH3 C20H12Cl2N4O 394 284-286 72 
KMK-107 2-Cl-5-Cl-phenyl 4-Br C19H9BrCl2N4O 458 298-300 65 
KMK-108 2-Cl-5-Cl-phenyl 3-Br C19H9BrCl2N4O 458 305-308 61 
KMK-109 2-Cl-5-Cl-phenyl 4-Cl C19H9Cl3N4O 414 278-282 70 
KMK-110 2-Cl-5-Cl-phenyl 3-Cl C19H9Cl3N4O 414 285-288 72 
KMK-111 3-Cl-4-Cl-phenyl H C19H10Cl2N4O 380 219-222 70 
KMK-112 3-Cl-4-Cl-phenyl 4-OCH3 C20H12Cl2N4O2 410 239-242 79 
KMK-113 3-Cl-4-Cl-phenyl 2-OCH3 C20H12Cl2N4O2 410 233-235 75 
KMK-114 3-Cl-4-Cl-phenyl 4-NO2 C19H9Cl2N5O3 425 248-250 68 
KMK-115 3-Cl-4-Cl-phenyl 2-NO2 C19H9Cl2N5O3 425 225-228 76 
KMK-116 3-Cl-4-Cl-phenyl 4-CH3 C20H12Cl2N4O 394 245-248 77 
KMK-117 3-Cl-4-Cl-phenyl 4-Br C19H9BrCl2N4O 458 257-260 69 
KMK-118 3-Cl-4-Cl-phenyl 3-Br C19H9BrCl2N4O 458 252-254 66 
KMK-119 3-Cl-4-Cl-phenyl 4-Cl C19H9Cl3N4O 414 210-212 70 
KMK-120 3-Cl-4-Cl-phenyl 3-Cl C19H9Cl3N4O 414 272-275 75 
KMK-121 4-F-phenyl H C19H11FN4O 330 238-240 75 
KMK-122 4-F-phenyl 4-OCH3 C20H13FN4O2 360 240-244 80 
KMK-123 4-F-phenyl 2-OCH3 C20H13FN4O2 360 260-262 75
KMK-124 4-F-phenyl 4-NO2 C19H10FN5O3 375 266-268 70
KMK-125 4-F-phenyl 2-NO2 C19H10FN5O3 375 255-258 79 
KMK-126 4-F-phenyl 4-CH3 C20H13FN4O 344 257-259 82 
KMK-127 4-F-phenyl 4-Br C19H10BrFN4O 408 249-252 75 
KMK-128 4-F-phenyl 3-Br C19H10BrFN4O 408 227-230 72 
KMK-129 4-F-phenyl 4-Cl C19H10ClFN4O 364 240-242 85 
KMK-130 4-F-phenyl 3-Cl C19H10ClFN4O 364 221-223 71
KMK-131 2-CH3-5-CH3-phenyl H C21H16N4O 340 283-285 68 
KMK-132 2-CH3-5-CH3-phenyl 4-OCH3 C22H18N4O2 370 255-260 71 
KMK-133 2-CH3-5-CH3-phenyl 2-OCH3 C22H18N4O2 370 225-228 74 
KMK-134 2-CH3-5-CH3-phenyl 4-NO2 C21H15N5O3 385 195-198 65 
KMK-135 2-CH3-5-CH3-phenyl 2-NO2 C21H15N5O3 385 228-230 69 
KMK-136 2-CH3-5-CH3-phenyl 4-CH3 C22H18N4O 354 220-222 74 
KMK-137 2-CH3-5-CH3-phenyl 4-Br C21H15BrN4O 418 275-279 70 
KMK-138 2-CH3-5-CH3-phenyl 3-Br C21H15BrN4O 418 290-292 75 
KMK-139 2-CH3-5-CH3-phenyl 4-Cl C21H15ClN4O 374 235-238 68 
KMK-140 2-CH3-5-CH3-phenyl 3-Cl C21H15ClN4O 374 258-260 72 
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2.4.2  Reaction Mechanism 
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2.5  Experimental 
 
2.5.1  Materials and Methods 
Melting points were determined in open capillary tubes and are 
uncorrected. Formation of the compounds was routinely checked by TLC on 
silica gel-G plates of 0.5 mm thickness and spots were located by iodine. IR 
spectra were recorded Shimadzu FT-IR-8400 instrument using KBr pellet 
method. Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model 
using Direct Injection Probe technique. 1H NMR was determined in DMSO-d6 
solution on a Bruker Ac 400 MHz spectrometer. Elemental analysis of the all 
the synthesized compounds was carried out on Elemental Vario EL III Carlo 
Erba 1108 model and the results are in agreements with the structures 
assigned. 
2.5.2 Synthesis of 2-cyano-N-(substituted) acetamides 
Synthesis of 2-cyano-N-(substituted) acetamides was prepared using 
previously published methods [101]. 
2.5.3 General procedure for the synthesis of 6-amino-1,2-dihydro-4-
(aryl)-2-oxo-1-(2,5-dichlorophenyl)pyridine-3,5-dicarbonitriles(KMK 101-
110). 
A mixture of 2-cyano-N-(2,5-dichlorophenyl) acetamide (0.01 mol), 
appropriate aromatic aldehydes (0.01 mol), malononitrile (0.01 mol) and 
catalytical amount of piperidine in methanol (20 ml) was heated under reflux 
condition for 15-16 hour. The reaction mixture was kept at room temperature 
for 2-4 hour. The solid product obtained was isolated and recrystallized from 
ethanol. 
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2.5.3.1 6-amino-1-(2,5-dichlorophenyl)-2-oxo-4-phenyl-1,2-dihydro 
pyridine-3,5-dicarbonitrile(KMK-101). 
 
 Yield: 71%;  MP: 272-2740C;  MS: m/z 380;. 
Elemental Analysis for C19H10Cl2N4O:   
Calculated: C, 59.86; H, 2.64; N, 14.70%.  
Found: C, 59.40; H, 2.30; N, 14.35%. 
 
 
2.5.3.2 6-amino-1-(2,5-dichlorophenyl)-4-(4-methoxyphenyl)-2-oxo-
1,2-dihydro pyridine-3,5-dicarbonitrile(KMK-102). 
 
 Yield: 66%;  MP: 280-2840C;  MS: m/z 410;  
Elemental Analysis for C20H12Cl2N4O2:   
Calculated: C, 58.41; H, 2.94; N, 13.62%.  
Found: C, 58.21; H, 2.45; N, 13.33%. 
 
 
2.5.3.3 6-amino-1-(2,5-dichlorophenyl)-4-(2-methoxyphenyl)-2-oxo-
1,2-dihydro pyridine-3,5-dicarbonitrile(KMK-103). 
 
Yield: 75%;  MP: 254-2580C;  MS: m/z 410;  
Elemental Analysis for C20H12Cl2N4O2:   
Calculated: C, 58.41; H, 2.94; N, 13.62%.  
Found: C, 58.26; H, 2.54; N, 13.46%. 
 
 
2.5.3.4 6-amino-1-(2,5-dichlorophenyl)-4-(4-nitrophenyl)-2-oxo-1,2-
dihydro pyridine-3,5-dicarbonitrile(KMK-104). 
 
Yield: 74%;  MP: 245-2500C;  MS: m/z 425;  
Elemental Analysis for C19H9Cl2N5O3:   
Calculated: C, 53.54; H, 2.13; N, 16.43%.  
Found: C,  53.22; H, 2.04; N, 16.18%. 
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2.5.3.5 6-amino-1-(2,5-dichlorophenyl)-4-(2-nitrophenyl)-2-oxo-1,2-
dihydro pyridine-3,5-dicarbonitrile(KMK-105). 
 
Yield: 78%;  MP: 234-2360C;  MS: m/z 425;  
Elemental Analysis for C19H9Cl2N5O3:   
Calculated: C, 53.54; H, 2.13; N, 16.43%.  
Found: C, 53.20; H, 2.08; N, 16.26%. 
 
2.5.3.6 6-amino-1-(2,5-dichlorophenyl)-2-oxo-4-(p-tolyl)-1,2-dihydro 
pyridine-3,5-dicarbonitrile(KMK-106). 
 
Yield: 72%;  MP: 284-2860C;  MS: m/z 394;  
Elemental Analysis for  C20H12Cl2N4O:   
Calculated: C, 60.78; H, 3.06; N, 14.18%.  
Found: C, 60.68; H, 3.00; N, 14.10%. 
 
2.5.3.7 6-amino-1-(2,5-dichlorophenyl)-4-(4-bromophenyl)-2-oxo-
1,2-dihydro pyridine-3,5-dicarbonitrile(KMK-107). 
 
Yield: 65%;  MP: 298-3000C;  MS: m/z 458;  
Elemental Analysis for C19H9BrCl2N4O:   
Calculated: C, 49.60; H, 1.97; N, 12.18%.  
Found: C, 49.37; H, 1.85; N, 12.07%. 
 
2.5.3.8 6-amino-1-(2,5-dichlorophenyl)-4-(3-bromophenyl)-2-oxo-
1,2-dihydro pyridine-3,5-dicarbonitrile(KMK-108). 
 
Yield: 61%;  MP: 305-3080C;  MS: m/z 458;  
Elemental Analysis for C19H9BrCl2N4O:   
Calculated: C, 49.60; H, 1.97; N, 12.18%.  
Found: C, 49.27; H, 1.90; N, 12.11%. 
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2.5.3.9 6-amino-1-(2,5-dichlorophenyl)-4-(4-chlorophenyl)-2-oxo-
1,2-dihydro pyridine-3,5-dicarbonitrile(KMK-109). 
 
Yield: 70%;  MP: 278-2820C;  MS: m/z 414;  
Elemental Analysis for C19H9Cl3N4O:   
Calculated: C, 54.90; H, 2.18 N, 13.48%.  
Found: C, 54.70; H, 2.10 N, 13.25%. 
 
2.5.3.10 6-amino-1-(2,5-dichlorophenyl)-4-(3-chlorophenyl)-2-oxo-
1,2-dihydro pyridine-3,5-dicarbonitrile(KMK-110). 
 
Yield: 72%;  MP: 285-2880C;  MS: m/z 414;  
Elemental Analysis for C19H9Cl3N4O:   
Calculated: C, 54.90; H, 2.18 N, 13.48%.  
Found: C, 54.55; H, 2.08 N, 13.14%. 
 
 
 
2.5.4 General procedure for the synthesis of 6-amino-1,2-dihydro-4-
(aryl)-2-oxo-1-(3,4-dichlorophenyl)pyridine-3,5-dicarbonitriles(KMK 111-
120). 
A mixture of 2-cyano-N-(3,4-dichlorophenyl) acetamide (0.01 mol), 
appropriate aromatic aldehydes (0.01 mol), malononitrile (0.01 mol) and 
catalytical amount of piperidine in methanol (20 ml) was heated under reflux 
condition for 15-16 hour. The reaction mixture was kept at room temperature 
for 2-4 hour. The solid product obtained was isolated and recrystallized from 
ethanol. 
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2.5.4.1 6-amino-1-(3,4-dichlorophenyl)-2-oxo-4-phenyl-1,2-dihydro 
pyridine-3,5-dicarbonitrile(KMK-111). 
 
Yield: 70%;  MP: 219-2220C;  MS: m/z 380;  
Elemental Analysis for C19H10Cl2N4O:   
Calculated: C, 59.86; H, 2.64; N, 14.70%.  
Found: C, 58.49; H, 2.30; N, 13.85%. 
 
2.5.4.2 6-amino-1-(3,4-dichlorophenyl)-4-(4-methoxyphenyl)-2-oxo-
1,2-dihydro pyridine-3,5-dicarbonitrile(KMK-112). 
 
Yield: 79%;  MP: 239-2420C;  MS: m/z 410;  
Elemental Analysis for C20H12Cl2N4O2:   
Calculated: C, 58.41; H, 2.94; N, 13.62%.  
Found: C, 57.89; H, 2.75; N, 13.53%. 
 
2.5.4.3 6-amino-1-(3,4-dichlorophenyl)-4-(2-methoxyphenyl)-2-oxo-
1,2-dihydro pyridine-3,5-dicarbonitrile(KMK-113). 
 
Yield: 75%;  MP: 233-2350C;  MS: m/z 410;  
Elemental Analysis for C20H12Cl2N4O2:   
Calculated: C, 58.41; H, 2.94; N, 13.62%.  
Found: C, 58.36; H, 2.59; N, 13.40%. 
 
 
2.5.4.4 6-amino-1-(3,4-dichlorophenyl)-4-(4-nitrophenyl)-2-oxo-1,2-
dihydro pyridine-3,5-dicarbonitrile(KMK-114). 
 
Yield: 68%;  MP: 248-2500C;  MS: m/z 425;  
Elemental Analysis for C19H9Cl2N5O3:   
Calculated: C, 53.54; H, 2.13; N, 16.43%.  
Found: C,  53.29; H, 1.95; N, 16.38%. 
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2.5.4.5 6-amino-1-(3,4-dichlorophenyl)-4-(2-nitrophenyl)-2-oxo-1,2-
dihydro pyridine-3,5-dicarbonitrile(KMK-115). 
 
Yield: 76%;  MP: 225-2280C;  MS: m/z 425;  
Elemental Analysis for C19H9Cl2N5O3:   
Calculated: C, 53.54; H, 2.13; N, 16.43%.  
Found: C,  53.35; H, 2.11; N, 16.36%. 
 
2.5.4.6 6-amino-1-(3,4-dichlorophenyl)-2-oxo-4-(p-tolyl)-1,2-dihydro 
pyridine-3,5-dicarbonitrile(KMK-116). 
 
Yield: 77%;  MP: 245-2480C;  MS: m/z 394;  
Elemental Analysis for  C20H12Cl2N4O:   
Calculated: C, 60.78; H, 3.06; N, 14.18%.  
Found: C, 60.65; H, 3.01; N, 14.15%. 
 
2.5.4.7 6-amino-1-(3,4-dichlorophenyl)-4-(4-bromophenyl)-2-oxo-
1,2-dihydro pyridine-3,5-dicarbonitrile(KMK-117). 
 
Yield: 69%;  MP: 257-2600C;  MS: m/z 458;  
Elemental Analysis for C19H9BrCl2N4O:   
Calculated: C, 49.60; H, 1.97; N, 12.18%.  
Found: C, 49.47; H, 1.95; N, 12.07%. 
 
 
2.5.4.8 6-amino-1-(3,4-dichlorophenyl)-4-(3-bromophenyl)-2-oxo-
1,2-dihydro pyridine-3,5-dicarbonitrile(KMK-118). 
 
Yield: 66%;  MP: 252-2540C;  MS: m/z 458;  
Elemental Analysis for C19H9BrCl2N4O:   
Calculated: C, 49.60; H, 1.97; N, 12.18%.  
Found: C, 49.47; H, 1.85; N, 12.15%. 
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2.5.4.9 6-amino-1-(3,4-dichlorophenyl)-4-(4-chlorophenyl)-2-oxo-
1,2-dihydro pyridine-3,5-dicarbonitrile(KMK-119). 
 
Yield: 70%;  MP: 210-2120C;  MS: m/z 414;  
Elemental Analysis for C19H9Cl3N4O:   
Calculated: C, 54.90; H, 2.18 N, 13.48%.  
Found: C, 54.80; H, 2.15 N, 13.29%. 
 
 
2.5.4.10 6-amino-1-(3,4-dichlorophenyl)-4-(3-chlorophenyl)-2-oxo-
1,2-dihydro pyridine-3,5-dicarbonitrile(KMK-120). 
 
Yield: 75%;  MP: 272-2750C;  MS: m/z 414;  
Elemental Analysis for C19H9Cl3N4O:   
Calculated: C, 54.90; H, 2.18 N, 13.48%.  
Found: C, 54.75; H, 2.13 N, 13.34%. 
 
 
2.5.5 General procedure for the synthesis of 6-amino-1,2-dihydro-4-
(aryl)-2-oxo-1-(4-Fluorophenyl)pyridine-3,5-dicarbonitriles(KMK 121-130). 
 
A mixture of 2-cyano-N-(4-Fluorophenyl) acetamide (0.01 mol), 
appropriate aromatic aldehydes (0.01 mol), malononitrile (0.01 mol) and 
catalytical amount of piperidine in methanol (20 ml) was heated under reflux 
condition for 15-16 hour. The reaction mixture was kept at room temperature 
for 2-4 hour. The solid product obtained was isolated and recrystallized from 
ethanol. 
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2.5.5.1 6-amino-1-(4-fluorophenyl)-2-oxo-4-phenyl-1,2-dihydro 
pyridine-3,5-dicarbonitrile(KMK-121). 
 
Yield: 75%;  MP: 238-2400C;  MS: m/z 330;  
Elemental Analysis for C19H11FN4O:   
Calculated: C, 69.09; H, 3.36; N, 16.96%.  
Found: C, 68.95; H, 3.32; N, 16.90%. 
 
 2.5.5.2 6-amino-1-(4-fluorophenyl)-4-(4-methoxyphenyl)-2-oxo-1,2-
dihydro pyridine-3,5-dicarbonitrile(KMK-122). 
 
Yield: 80%;  MP: 240-2440C;  MS: m/z 360;  
Elemental Analysis for C20H13FN4O2:   
Calculated: C, 66.66; H, 3.64; N, 15.55%.  
Found: C, 66.56; H, 3.54; N, 15.45%. 
 
2.5.5.3 6-amino-1-(4-fluorophenyl)-4-(2-methoxyphenyl)-2-oxo-1,2-
dihydro pyridine-3,5-dicarbonitrile(KMK-123). 
 
Yield: 75%;  MP: 260-2620C;  MS: m/z 360;  
Elemental Analysis for C20H13FN4O2:   
Calculated: C, 66.66; H, 3.64; N, 15.55%.  
Found: C, 66.58; H, 3.54; N, 15.50%. 
 
2.5.5.4 6-amino-1-(4-fluorophenyl)-4-(4-nitrophenyl)-2-oxo-1,2-
dihydro pyridine-3,5-dicarbonitrile(KMK-124). 
 
Yield: 70%;  MP: 266-2680C;  MS: m/z 375;  
Elemental Analysis for C19H10FN5O3:   
Calculated: C, 60.80; H, 2.69; N, 18.66%.  
Found: C, 60.75; H, 2.63; N, 18.60%. 
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2.5.5.5 6-amino-1-(4-fluorophenyl)-4-(2-nitrophenyl)-2-oxo-1,2-
dihydro pyridine-3,5-dicarbonitrile(KMK-125). 
 
Yield: 79%;  MP: 255-2580C;  MS: m/z 375;  
Elemental Analysis for C19H10FN5O3:   
Calculated: C, 60.80; H, 2.69; N, 18.66%.  
Found: C, 60.78; H, 2.65; N, 18.56%. 
 
2.5.5.6 6-amino-1-(4-fluorophenyl)-2-oxo-4-(p-tolyl)-1,2-dihydro 
pyridine-3,5-dicarbonitrile(KMK-126). 
 
Yield: 82%;  MP: 257-2590C;  MS: m/z 344;  
Elemental Analysis for C20H13FN4O:   
Calculated: C, 69.76; H, 3.81; N, 16.27%.  
Found: C, 69.70; H, 3.71; N, 16.23%. 
 
2.5.5.7 6-amino-1-(4-fluorophenyl)-4-(4-bromophenyl)-2-oxo-1,2-
dihydro pyridine-3,5-dicarbonitrile(KMK-127). 
 
Yield: 75%;  MP: 249-2520C;  MS: m/z 408;  
Elemental Analysis for C19H10BrFN4O:   
Calculated:C, 55.77; H, 2.46; N, 13.69%.  
Found: C, 55.70; H, 2.40; N, 13.66%. 
 
2.5.5.8 6-amino-1-(4-fluorophenyl)-4-(3-bromophenyl)-2-oxo-1,2-
dihydro pyridine-3,5-dicarbonitrile(KMK-128). 
 
Yield: 72%;  MP: 227-2300C;  MS: m/z 408;  
Elemental Analysis for C19H10BrFN4O:   
Calculated: C, 55.77; H, 2.46; N, 13.69%.  
Found: C, 55.74; H, 2.42; N, 13.64%. 
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2.5.5.9 6-amino-1-(4-fluorophenyl)-4-(4-chlorophenyl)-2-oxo-1,2-
dihydro pyridine-3,5-dicarbonitrile(KMK-129). 
 
Yield: 85%;  MP: 240-2420C;  MS: m/z 364;  
Elemental Analysis for C19H10ClFN4O:   
Calculated: C, 62.56; H, 2.76; N, 15.36%.  
Found: C, 62.51; H, 2.70; N, 15.32%. 
 
2.5.5.10 6-amino-1-(4-fluorophenyl)-4-(3-chlorophenyl)-2-oxo-1,2-
dihydro pyridine-3,5-dicarbonitrile(KMK-130). 
 
Yield: 71%;  MP: 221-2230C;  MS: m/z 364;  
Elemental Analysis for C19H10ClFN4O:   
Calculated: C, 62.56; H, 2.76; N, 15.36%.  
Found: C, 62.46; H, 2.56; N, 15.30% 
 
 
2.5.6 General procedure for the synthesis of 6-amino-1,2-dihydro-4-
(aryl)-2-oxo-1-(2,5-dimethylhenyl)pyridine-3,5-dicarbonitriles(KMK 131-
140). 
A mixture of 2-cyano-N-(2,5-dimethylphenyl) acetamide (0.01 mol), 
appropriate aromatic aldehydes (0.01 mol), malononitrile (0.01 mol) and 
catalytical amount of piperidine in methanol (20 ml) was heated under reflux 
condition for 20-22 hour. The reaction mixture was kept at room temperature 
for 2-4 hour. The solid product obtained was isolated and recrystallized from 
ethanol. 
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 2.5.6.1 6-amino-1-(2,5-dimethylhenyl)-2-oxo-4-phenyl-1,2-dihydro 
pyridine-3,5-dicarbonitrile(KMK-131). 
 
Yield: 68%;  MP: 283-2850C;  MS: m/z 340;  
Elemental Analysis for C21H16N4O:   
Calculated: C, 74.10; H, 4.74; N, 16.46%.  
Found: C, 74.06; H, 4.64; N, 16.56%. 
 
 2.5.6.2 6-amino-1-(2,5-dimethylhenyl)-4-(4-methoxyphenyl)-2-oxo-
1,2-dihydro pyridine-3,5-dicarbonitrile(KMK-132). 
 
Yield: 71%;  MP: 255-2600C;  MS: m/z 370;  
Elemental Analysis for C22H18N4O2:   
Calculated: C, 71.34; H, 4.90; N, 15.13%.  
Found: C, 71.30; H, 4.87; N, 15.08%. 
 
2.5.6.3 6-amino-1-(2,5-dimethylhenyl)-4-(2-methoxyphenyl)-2-oxo-
1,2-dihydro pyridine-3,5-dicarbonitrile(KMK-133). 
 
Yield: 74%;  MP: 225-2280C;  MS: m/z 370;  
Elemental Analysis for C22H18N4O2:   
Calculated: C, 71.34; H, 4.90; N, 15.13%.  
Found: C, 71.31; H, 4.85; N, 15.10%. 
 
2.5.6.4 6-amino-1-(2,5-dimethylhenyl)-4-(4-nitrophenyl)-2-oxo-1,2-
dihydro pyridine-3,5-dicarbonitrile(KMK-134). 
 
Yield: 65%;  MP: 195-1980C;  MS: m/z 385;  
Elemental Analysis for C21H15N5O3:   
Calculated: C, 65.45; H, 3.92; N, 18.17%.  
Found: C, 65.40; H, 3.91; N, 18.15%. 
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2.5.6.5 6-amino-1-(2,5-dimethylhenyl)-4-(2-nitrophenyl)-2-oxo-1,2-
dihydro pyridine-3,5-dicarbonitrile(KMK-135). 
 
Yield: 69%;  MP: 228-2300C;  MS: m/z 385;  
Elemental Analysis for C21H15N5O3:   
Calculated: C, 65.45; H, 3.92; N, 18.17%.  
Found: C, 65.35; H, 3.88; N, 18.10%. 
 
2.5.6.6 6-amino-1-(2,5-dimethylhenyl)-2-oxo-4-(p-tolyl)-1,2-dihydro 
pyridine-3,5-dicarbonitrile(KMK-136). 
 
Yield: 74%;  MP: 220-2220C;  MS: m/z 354;  
Elemental Analysis for C22H18N4O:   
Calculated: C, 74.56; H, 5.12; N, 15.81%.  
Found: C, 74.50; H, 5.11; N, 15.71%. 
 
2.5.6.7 6-amino-1-(2,5-dimethylhenyl)-4-(4-bromophenyl)-2-oxo-1,2-
dihydro pyridine-3,5-dicarbonitrile(KMK-137). 
 
Yield: 70%;  MP: 275-2790C;  MS: m/z 418;  
Elemental Analysis for C21H15BrN4O:   
Calculated: C, 60.16; H, 3.61; N, 13.36%.  
Found: C, 60.11; H, 3.51; N, 13.31%. 
 
2.5.6.8 6-amino-1-(2,5-dimethylhenyl)-4-(3-bromophenyl)-2-oxo-1,2-
dihydro pyridine-3,5-dicarbonitrile(KMK-138). 
 
Yield: 75%;  MP: 290-2920C;  MS: m/z 418;  
Elemental Analysis for C21H15BrN4O:   
Calculated: C, 60.16; H, 3.61; N, 13.36%.  
Found: C, 60.13; H, 3.57; N, 13.31%. 
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2.5.6.9 6-amino-1-(2,5-dimethylhenyl)-4-(4-chlorophenyl)-2-oxo-1,2-
dihydro pyridine-3,5-dicarbonitrile(KMK-139). 
 
Yield: 68%;  MP: 235-2380C;  MS: m/z 374;  
Elemental Analysis for C21H15ClN4O:   
Calculated: C, 67.29; H, 4.03; N, 14.95%.  
Found: C, 67.25; H, 3.95; N, 14.89%. 
 
2.5.6.10 6-amino-1-(2,5-dimethylhenyl)-4-(3-chlorophenyl)-2-oxo-1,2-
dihydro pyridine-3,5-dicarbonitrile(KMK-140). 
 
Yield: 72%;  MP: 258-2600C;  MS: m/z 374;  
Elemental Analysis for C21H15ClN4O:   
Calculated: C, 67.29; H, 4.03; N, 14.95%.  
Found: C, 67.25; H, 4.00; N, 14.92%. 
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2.6  Spectral Discussion 
2.6.1  IR Spectral Study 
IR spectra were recorded on Shimadzu FT-IR-8400 model using KBr 
pellet method. Various functional groups present in molecule were identified 
by characteristic frequency obtained for them. For 3-cyano-2-pyridones (KMK-
101 to 140), confirmatory bands for primary amine (-NH2), carbonyl (C=O) and 
nitrile (C≡N) stretching band was observed at 3250-3500 cm-1, 1630-1700 cm-
1 and 2200-2230 cm-1 respectively. Another characteristic band for N-H 
deformation and C-N stretching were observed at 1500-1600 cm-1 and 1200-
1360 cm-1 respectively, which suggested the formation of pyridone ring. 
 
2.6.2  1H NMR Spectral Study 
1H NMR spectra were recorded in DMSO-d6 solution on a Bruker Ac 
400 MHz spectrometer using TMS as an internal standard. Number of protons 
and their chemical shifts were found to support the structure of the 
synthesized compounds. 
1H NMR spectra confirmed the structures of 3-cyano-2-pyridones 
(KMK-101 to 140) on the basis of following signals: singlet for primary amino 
group proton was observed at 7.50-7.90 δ ppm. The aromatic ring protons 
and J value were found to be in accordance with substitution pattern on 
phenyl ring.  
 
2.6.3  Mass Spectral Study 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model 
using Direct Injection Probe technique. Systematic fragmentation pattern was 
observed in mass spectral analysis. Molecular ion peak was observed in 
agreement with molecular weight of respective compound. Mass 
fragmentation pattern for a representative compound of each series is 
mention here. 
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IR spectra of KMK-102 
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Sr. No. Frequency (cm-1) Vibration Mode 
1 3665 &3522 N-H Streching of primary amine 
2 3194 C-H Streching of aromatic ring 
3 2218 C≡N Streching of nitrial group 
4 1639 C=O Steching of pyridone ring 
5 1525 N-H deformation of NH2 group 
6 1461 C=C Steching of aromatic ring 
7 1252 C-N Streching of carbon bonded to amine 
8 1173 C-O-C symmetrical stretching OCH3 group 
9 1095 C-H in plane bending for aromatic ring 
10 830 out of plane bending for disubstituted aromatic ring 
11 774 C-Cl Streching 
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1H-NMR spectra of KMK-102 
 
 
Signal 
No. 
 
Signal Position
δppm 
Relative No. 
of Protons 
 
Multiplicity 
 
 
Inference 
 
1 3.85 3 Singlet OCH3(a) 
2 7.12-7.15 2 doublet Ar-CH(b-b’)  (J=11.6 mHz) 
3 7.52-7.55 2 doublet Ar-CH(c-c’) (J=11.6 mHz) 
4 7.68-7.69 1 doublet/quartet Ar-CH(d) 
5 7.75-7.78 1 doublet Ar-CH(e) (J=11.6 mHz) 
5 7.85 1 Singlet Ar-CH(f) 
6 8.28 2 Singlet NH2(g) 
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Expanded 1H-NMR spectra of KMK-102 
 
Mass spectra of KMK-102 
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Mass fragmentation pattern for KMK-102 
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IR spectra of KMK-116 
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Sr. No. Frequency (cm-1) Vibration Mode 
1 3457 & 3299 N-H Streching of primary amine 
2 3202 C-H Streching of aromatic ring 
3 2837 C-H Streching of CH3 group 
4 2213 C≡N Streching of nitrial group 
5 1685 C=O Steching of pyridone ring 
6 1617 N-H deformation of NH2 group 
7 1514 & 1456 C=C Steching of aromatic ring 
8 1253 C-N Streching of carbon bonded to amine 
9 1027 C-H in plane bending for aromatic ring 
10 828 Out of plane bending for disubstituted aromatic ring 
11 771 C-Cl Streching 
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1H-NMR spectra of KMK-116 
 
 
Signal 
No. 
 
 
Signal Position 
δppm 
 
 
Relative No. 
of Protons 
 
 
Multiplicity 
 
 
Inference 
 
1 2.02 3 Singlet CH3(a) 
2 7.12-7.15 2 doublet Ar-CH(b-b’) (J=11.6mHz) 
3 7.44-7.51 3 Multiplate Ar-CH(d,e,f) 
4 7.85-7.87 2 doublet Ar-CH(c-c’) 
5 8.00 2 Singlet NH2(g) 
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Expanded 1H-NMR spectra of KMK-116 
 
Mass spectra of KMK-116 
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Mass fragmentation pattern for KMK-116 
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IR spectra of KMK-122 
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Sr. No. Frequency (cm-1) Vibration Mode 
1 3384 &3317 N-H Streching of primary amine 
2 3201 C-H Streching of aromatic ring 
3 2209 C≡N Streching of nitrial group 
4 1608 C=O Steching of pyridone ring 
5 1516 N-H deformation of NH2 group 
6 1455 C=C Steching of aromatic ring 
7 1297 C-N Streching of carbon bonded to amine 
8 1254 C-F Streching 
9 1172 C-O-C symmetrical stretching OCH3 group 
10 1022 C-H in plane bending for aromatic ring 
11 830 out of plane bending for disubstituted aromatic ring 
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1H-NMR spectra of KMK-122 
 
 
Signal 
No. 
 
 
Signal Position 
δppm 
 
 
Relative No. 
of Protons 
 
 
Multiplicity 
 
 
Inference 
 
1 3.85 3 Singlet OCH3(a) 
2 7.11-7.14 2 doublet Ar-CH(b-b’) (J=12 mHz) 
3 7.41-7.52 6 Multiplate Ar-CH(cc’,dd’,ee’) 
4 7.9 2 Singlet NH2(f) 
 
 
 
# ee’-indicate the triplet due to F atom. 
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Expanded 1H-NMR spectra of KMK-122 
 
Mass spectra of KMK-122 
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Mass fragmentation pattern for KMK-122 
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IR spectra of KMK-137 
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Sr. No. Frequency (cm-1) Vibration Mode 
1 3651 & 3447 N-H Streching of primary amine 
2 3206 C-H Streching of aromatic ring 
3 2215 C≡N Streching of nitrial group 
4 1631 C=O Steching of pyridone ring 
5 1528 N-H deformation of NH2 group 
6 1460 C=C Steching of aromatic ring 
7 1228 C-N Streching of carbon bonded to amine 
8 1011 C-H in plane bending for aromatic ring 
9 822 out of plane bending for disubstituted aromatic ring 
10 642 C-Br stretching 
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1H-NMR spectra of KMK-137 
 
 
Signal 
No. 
 
 
Signal Position 
δppm 
 
 
Relative No. 
of Protons 
 
 
Multiplicity 
 
 
Inference 
 
1 2.02 3 Singlet CH3(a) 
2 2.32 3 Singlet CH3(b) 
3 7.11 1 Singlet Ar-CH(c) 
4 7.25-7.35 2 doublet Ar-CH(d,e) 
5 7.53-7.56 2 doublet Ar-CH(f-f’) (J=11.2mHz) 
6 7.79-7.82 2 doublet Ar-CH(g-g’) (J=11.6mHz) 
7 7.93 2 Singlet NH2(h) 
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Expanded 1H-NMR spectra of KMK-137 
 
Mass spectra of KMK-137 
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Mass fragmentation pattern for KMK-137 
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2.7  Biological Evaluation 
2.7.1  Antimicrobial Evaluation 
All the synthesized compounds (KMK-101 to KMK-140) were tested for 
their antibacterial and antifungal activity (MIC) in vitro by broth dilution method 
[102, 103] with two Gram-positive bacteria Staphylococcus aureus MTCC-96, 
Streptococcus pyogenes MTCC 443, two Gram-negative bacteria Escherichia 
coli MTCC 442, Pseudomonas aeruginosa MTCC 441 and three fungal 
strains Candida albicans MTCC 227, Aspergillus Niger MTCC 282, 
Aspergillus clavatus MTCC 1323 taking ampicillin, chloramphenicol, 
ciprofloxacin, norfloxacin, nystatin, and greseofulvin as standard drugs. The 
standard strains were procured from the Microbial Type Culture Collection 
(MTCC) and Gene Bank, Institute of Microbial Technology, Chandigarh, India.  
 The minimal inhibitory concentration (MIC) values for all the newly 
synthesized compounds, defined as the lowest concentration of the 
compound preventing the visible growth, were determined by using micro 
dilution broth method according to NCCLS standards [102]. Serial dilutions of 
the test compounds and reference drugs were prepared in Muellere-Hinton 
agar. Drugs (10 mg) were dissolved in dimethylsulfoxide (DMSO, 1 mL). 
Further progressive dilutions with melted Muellere-Hinton agar were 
performed to obtain the required concentrations. In primary screening 1000 μg 
mL-1, 500 μg mL-1 and 250 μg mL-1 concentrations of the synthesized drugs 
were taken. The active synthesized drugs found in this primary screening 
were further tested in a second set of dilution at 200 μg mL-1, 100 μg mL-1, 50 
μg mL-1, 25 μg mL-1, 12.5 μg mL-1, and 6.25 μg mL-1 concentration against all 
microorganisms. The tubes were inoculated with 108 cfu mL-1 (colony forming 
unit/mL) and incubated at 37 ºC for 24 h. The MIC was the lowest 
concentration of the tested compound that yields no visible growth (turbidity) 
on the plate. To ensure that the solvent had no effect on the bacterial growth, 
a control was performed with the test medium supplemented with DMSO at 
the same dilutions as used in the experiments and it was observed that 
DMSO had no effect on the microorganisms in the concentrations studied. 
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Antibacterial and antifungal activity of synthesized compounds KMK-
101 to 140 
Code 
Antibacterial Activity Antifungal Activity 
Minimal Bactericidal 
Concentration μg/ml Minimal Fungicidal 
Concentration μg/ml Gram +ve 
Bacteria 
Gram –ve 
Bacteria 
S.a. S.p. E.c. P.a. C.a. A.n. A.c. 
KMK-101 100 62.5 250 250 >1000 500 100 
KMK-102 100 500 62.5 250 500 >1000 1000 
KMK-103 200 250 200 100 500 1000 1000 
KMK-104 100 500 125 1000 500 1000 1000 
KMK-105 250 1000 250 500 500 250 250 
KMK-106 1000 500 1000 1000 500 500 1000 
KMK-107 100 62.5 125 100 500 500 500 
KMK-108 100 1000 250 1000 1000 500 1000 
KMK-109 250 250 100 500 100 500 500 
KMK-110 125 100 100 500 500 100 1000 
KMK-111 200 500 250 250 >1000 >1000 >1000 
KMK-112 250 500 500 200 >1000 500 >1000 
KMK-113 200 100 250 62.5 500 500 >1000 
KMK-114 250 250 100 250 500 1000 100 
KMK-115 500 500 200 250 500 1000 500 
KMK-116 200 200 100 100 500 >1000 1000 
KMK-117 500 250 200 100 500 1000 1000 
KMK-118 200 250 100 250 >1000 >1000 1000 
KMK-119 250 500 250 500 >1000 1000 1000 
KMK-120 200 200 100 250 500 1000 >1000 
KMK-121 500 100 500 200 >1000 >1000 >1000 
KMK-122 500 500 250 500 >1000 >1000 >1000 
KMK-123 200 200 100 200 1000 1000 100 
KMK-124 250 250 100 100 >1000 >1000 >1000 
KMK-125 250 500 200 250 500 1000 >1000 
KMK-126 200 200 500 500 >1000 1000 >1000 
KMK-127 500 500 250 250 >1000 100 >1000 
KMK-128 200 100 200 250 1000 1000 >1000 
KMK-129 100 250 250 200 500 >1000 100
KMK-130 500 100 100 250 1000 1000 250 
KMK-131 500 500 250 200 >1000 >1000 >1000 
KMK-132 250 200 150 100 500 500 250 
KMK-133 200 500 250 500 250 500 >1000 
KMK-134 100 500 250 200 >1000 >1000 >1000 
KMK-135 250 250 62.5 250 1000 1000 500 
KMK-136 500 500 250 500 250 >1000 >1000 
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KMK-137 100 50 250 200 500 100 250 
KMK-138 250 250 500 250 1000 500 >1000 
KMK-139 200 250 500 500 500 250 500 
KMK-140 500 100 500 500 >1000 >1000 >1000 
     
Minimal Inhibition Concentration 
 
Standard Drugs S.aureus S.pyogenus E.coli  P.aeruginosa 
(microgramme/ml) 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
 
Minimal Fungicidal Concentration 
 
Standard Drugs C.Albicans  A.Niger  A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
Greseofulvin 500 100 100 
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Chapter 3 
Microwave Assisted Synthesis and 
Biological Evaluation of Pyrido [2, 
3-d]pyrimidine 
 
 
3.1      Introduction 
Bicyclic nitrogen-containing heterocyclic compounds, such as purines, 
[1-3] quinazolines, [4-6] pteridines and pyrido-pyrimidines[7-8] are well-known 
pharmacophores in drug discovery. Examples of marketed drugs with a 
bicyclic core structure include gefitinib and erlotinib, which are both 
quinazoline analogues acting as receptor tyrosine kinase inhibitors and which 
are both used for the treatment of non-small cell lung cancer. Prazosin is a 
α1-antagonist based on a quinazoline scaffold, used as antihypertensive and 
for the treatment of benign prostate hypertrophy.  
Triamterene and methotrexate are both pteridine derivatives. 
Triamterene is approved for the treatment of hypertension. Methotrexate is an 
inhibitor of human dihydrofolate reductase (DHFR) and was originally 
developed as an anti-cancer compound, but is also extensively used for the 
treatment of rheumatoid arthritis. Theophylline is a purine analogue used for 
the treatment of asthma. Purines are also important constituents as the base 
moiety of antiviral nucleosides, such as didanosine and abacavir, which both 
are licensed as antiretroviral medication. 
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  The pyridopyrimidine scaffold is also extensively described as 
heterocycle in different drug discovery programs. There are four possible 
isomeric structures for pyrido[d]pyrimidines, depending on the position of the 
nitrogen atom in the pyridine moiety. 
N
N
N
pyrido[3,2-d]pyrimidine
N
N
N
N
N
N
N
N N
pyrido[4,3-d]pyrimidine
pyrido[3,4-d]pyrimidine pyrido[2,3-d]pyrimidine
Isomeric pyrido[d]pyrimidine  
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Pyrido[2,3-d]pyrimidines have been the most thoroughly investigated of 
the four ring systems and hence, this scaffold is associated with a wide range 
of biological activities, such as dihydrofolate reductase (DHFR) inhibitory 
activity, antitumor activity, [9-11] adenosine kinase inhibition[12] and tyrosine 
kinase inhibition. [13]  
Pyrido[3,2-d]pyrimidines have been described as tyrosine kinase 
inhibitors, [14] as dihydrofolate reductase inhibitors, [15] as anti-HCV agents[16-17] 
and as immunosuppressive drugs. [18]  
Pyrido[3,4-d]pyrimidines are well known to be potent tyrosine kinase 
inhibitors[19-20] and matrix metalloproteinase-13 (MMP-13) inhibitors. [21]  
 Pyrido[4,3- d]pyrimidines have been identified as inhibitors of tyrosine 
kinases of the epidermal growth factor receptor family[22-23], but overall this 
scaffold seems to be underused in medicinal chemistry programs. 
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As part of an ongoing medicinal chemistry research program to 
discover anti-inflammatory agents based on TNF inhibition, we very much got 
interested in the synthesis of pyrido[2,3- d]pyrimidine analogues. This type of 
compounds possesses five possible substitution sites (R2, R4, R5, R7, R8), 
which means that the number and combination of substituent’s that ultimately 
can lead to a drug is very high. Therefore, there is a clear need for synthetic 
schemes that can be used for rapidly exploring the structure-activity 
relationship (SAR) of the pyrido[2,3- d]pyrimidine scaffold. 
 
 
 
The synthetic schemes described in literature for the preparation of 
pyrido[2,3-d]pyrimidine analogues allow only to introduce structural variety in 
one or two particular positions of the scaffold.[24-26] To our knowledge, there 
are no systematic studies done on how to elaborate in a systematic way the 
chemistry of this compound class. Therefore, the main goal of this research is 
to develop synthetic schemes that can be easily adapted for use in parallel 
chemistry, and hence are suitable to establish structure-activity relationship 
studies. In that respect, we will try to introduce a broad structural variety into 
the pyrido[2,3-d]pyrimidine scaffold in which three or more substitution sites 
can be varied in one synthetic cycle. 
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3.2  Microwave-Assisted Organic Synthesis (MAOS) – A Brief History 
While fire is now rarely used in synthetic chemistry, it was not until 
Robert Bunsen invented the burner in 1855 that the energy from this heat 
source could be applied to a reaction vessel in a focused manner. The 
Bunsen burner was later superseded by the mantle, the oil bath or the hot 
plate as a means of applying heat to a chemical reaction. In the past few 
years, heating and driving chemical reactions by microwave energy has been 
an increasingly popular theme in the scientific community [27, 28]. 
Microwave energy, originally applied for heating food stuffs by Percy 
Spencer in the 1940s, has found a variety of technical applications in the 
chemical and related industries since the 1950s, in particular in the food-
processing, drying and polymer industries. Other applications range from 
analytical chemistry (microwave digestion, ashing and extraction) [29] to 
biochemistry (protein hydrolysis, sterilization) [29], pathology (histoprocessing, 
tissue fixation) [30] and medical treatments (diathermy) [31]. Somewhat 
surprisingly, microwave heating has only been implemented in organic 
synthesis since the mid-1980s. The first reports on the use of microwave 
heating to accelerate organic chemical transformations (MAOS) were 
published by the groups of Richard Gedye (Scheme 3.1) [32] and Raymond J. 
Giguere/George Majetich [33] in 1986.  
NH2
O
OH
O
20% H2SO4
MW or thermal
Thermal: 1h, 90% yield (reflux)
MW: 10 min, 99% yield (sealed vessel)
Scheme 3.1  
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In those early days, experiments were typically carried out in sealed 
Teflon or glass vessels in a domestic household microwave oven without any 
temperature or pressure measurements. The results were often violent 
explosions due to the rapid uncontrolled heating of organic solvents under 
closed-vessel conditions. In the 1990s, several groups started to experiment 
with solvent-free microwave chemistry (so-called dry-media reactions), which 
eliminated the danger of explosions [34]. Here, the reagents were pre-
adsorbed onto either an essentially microwave-transparent (i.e., silica, 
alumina or clay) or strongly absorbing (i.e., graphite) inorganic support, that 
additionally may have been doped with a catalyst or reagent. Particularly in 
the early days of MAOS, the solvent-free approach was very popular since it 
allowed the safe use of domestic microwave ovens and standard open-vessel 
technology. While a large number of interesting transformations using “dry-
media” reactions have been published in the literature [34], technical difficulties 
relating to non-uniform heating, mixing and the precise determination of the 
reaction temperature remained unresolved, in particular when scale-up issues 
needed to be addressed. 
Alternatively, microwave-assisted synthesis has been carried out using 
standard organic solvents under open-vessel conditions. If solvents are 
heated by microwave irradiation at atmospheric pressure in an open vessel, 
the boiling point of the solvent typically limits the reaction temperature that 
can be achieved. In order to nonetheless achieve high reaction rates, high-
boiling microwave-absorbing solvents have been frequently used in open-
vessel microwave synthesis [35]. However, the use of these solvents presented 
serious challenges in relation to product isolation and recycling of the solvent. 
Because of the recent availability of modern microwave reactors with on-line 
monitoring of both temperature and pressure, MAOS in dedicated sealed 
vessels using standard solvents-a technique pioneered by Christopher R. 
Strauss in the mid-1990s [36] has been celebrating a comeback in recent 
years. This is clearly evident surveying the recently published (since 2001) 
literature in the area of controlled microwave-assisted organic synthesis 
(MAOS). It appears that the combination of rapid heating by microwaves with 
sealed-vessel (autoclave) technology will most likely be the method of choice 
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for performing MAOS on a laboratory scale in the future. Importantly, recent 
innovations in microwave reactor technology now allow controlled parallel and 
automated sequential processing under sealed-vessel conditions, and the use 
of continuous- or stop-flow reactors for scale-up purposes. 
Since the early days of microwave synthesis, the observed rate 
accelerations and sometimes altered product distributions compared to oil-
bath experiments have led to speculation on the existence of so-called 
“specific” or “non-thermal” microwave effects [37]. Historically, such effects 
were claimed when the outcome of a synthesis performed under microwave 
conditions was different from that of the conventionally heated counterpart at 
the same apparent temperature. Reviewing the present literature [38], it 
appears that today most scientists agree that in the majority of cases the 
reason for the observed rate enhancements is a purely thermal/kinetic effect, 
i.e., a consequence of the high reaction temperatures that can rapidly be 
attained when irradiating polar materials in a microwave field, although effects 
that are caused by the unique nature of the microwave dielectric heating 
mechanism (“specific microwave effects”) clearly also need to be considered. 
While for the medicinal chemist in industry this discussion may seem largely 
irrelevant, the debate on “microwave effects” is undoubtedly going to continue 
for many years in the academic world. Regardless of the nature of the 
observed rate enhancements, microwave synthesis has now truly matured 
and has moved from a laboratory curiosity in the late 1980s to an established 
technique in organic synthesis, heavily used in both academia and industry. 
The initially slow uptake of the technology in the late 1980s and 1990s 
has been attributed to its lack of controllability and reproducibility, coupled 
with a general lack of understanding of the basics of microwave dielectric 
heating. The risks associated with the flammability of organic solvents in a 
microwave field and the lack of available dedicated microwave reactors 
allowing for adequate temperature and pressure control were major concerns. 
Important instrument innovations now allow for careful control of time, 
temperature and pressure profiles, paving the way for reproducible protocol 
development, scale-up and transfer from laboratory to laboratory and from 
scientist to scientist. Today, microwave chemistry is as reliable as the vast 
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arsenal of synthetic methods that preceded it. Since 2001, therefore, the 
number of publications related to MAOS has increased dramatically, to such a 
level that it might be assumed that, in a few years, most chemists will 
probably use microwave energy to heat chemical reactions on a laboratory 
scale [27, 28]. Not only is direct microwave heating able to reduce chemical 
reaction times significantly, but it is also known to reduce side reactions, 
increase yields and improve reproducibility. Therefore, many academic and 
industrial research groups are already using MAOS as a technology for rapid 
reaction optimization, for the efficient synthesis of new chemical entities or for 
discovering and probing new chemical reactivity. 
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3.3  Applications of Microwaves in Heterocyclic Ring Formation 
3.3.1  Five-membered heterocyclic rings 
3.3.1.1 Pyrroles 
The classical Paal-Knorr cyclization of 1,4-diketones to give pyrroles is 
dramatically speeded-up under microwave irradiation and high yields are 
obtained as shown in Scheme 3.2 [39]. 
 
3.3.1.2 Pyrazoles 
Another recent application of microwaves in cyclization is the 
preparation of pyrazoles from hydrazones using the Vilsmeier cyclization 
method by treatment with POCl3 and DMF 
[40].
 
As shown in Scheme 3.3, once 
again the reaction is speeded-up by several factors 100-fold. 
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3.3.1.3 Imidazoles 
An important classical preparation of imidazoles is from an α-diketone, 
an aldehyde and ammonia. Here again, excellent yields can be obtained in 
reaction times of a few minutes as shown in Scheme 3.4 [41]. 
 
3.3.1.4 Oxazolines 
The example of Scheme 3.5, the preparation of oxazolines shows that 
partially saturated five-membered rings can also be prepared advantageously 
using microwaves [42]. 
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3.3.1.5 Triazoles and tetrazoles 
Schemes 3.6 and 3.7 continue the overview of five-membered rings 
with illustrations of the advantageous preparation of tetrazoles (Scheme 3.6) 
[43] and 1,2,4-triazoles (Scheme 3.7) [44] using microwaves. Notice that in 
Scheme 3.6 the starting aryl cyanides are also made by a Pd-catalyzed but 
microwave-enhanced replacement of aryl bromides using zinc cyanide. 
 
 
3.3.1.6 Oxadiazoles 
The dehydration of unsymmetrical diacylhydrazines (themselves 
prepared by a conventional Mitsunobu reaction) using Burgess’s reagent is 
shown in Scheme 3.8 to give 1,3,4-oxadiazoles rapidly under microwave 
irradiation [45]. 
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MW: 150 ºC, 5 min., DMF
Convential :90 min., 150 ºC
R = alkyl, aryl; R2 = Cl, OMe
Scheme 3.8
+
R1 OH
O
N
H
O
H2N
R2
DDC
N
H
OH
N
R2
R1
O
MeO N
S
NEt3
O O
O
NN
OR1
100%
 
3.3.1.7 Isoxazolines and pyrazolines 
The acceleration of 1,3-dipolar cycloaddition reactions to give 
isoxazolines and pyrazolines by the addition of activated olefins to nitrile 
oxides or nitrile imides, respectively, is illustrated in Scheme 3.9; the resulting 
compounds are obtained in far high yield than under conventional conditions 
[46]. 
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3.3.2  Benzo-derivatives of five-membered rings 
3.3.2.1 Benz-imidazoles, -oxazoles, and –thiazoles 
Ring closure reactions of appropriate o-substituted anilines to give 
benzimidazoles, benzoxazoles, and benzthiazoles takes place much faster 
and in significantly high yield under microwave conditions  than conventionally 
[47] as shown in Scheme 3.10.  
 
3.3.2.2 Indoles 
The classical Fischer-indole synthesis from an aryl hydrazine and a 
ketone is speeded-up by several 100-fold as documented in Scheme 3.11 [48].  
 
3.3.2.3 γ-Carbolines 
The Graebe-Ullmann synthesis which converts 1-arylbenzotriazoles 
into carbazoles or their heterocyclic analogs is also accelerated under 
microwave conditions as shown in Scheme 3.12 where the 1-(4-
pyridyl)benzotriazole is converted into a γ-carboline [49].  
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3.3.3  Six-membered rings 
3.3.3.1 Dihydropyridines   
The Hantzsch dihydropyridine synthesis remains one of the most 
important routes to pyridine ring systems. Under conventional conditions long 
periods of heating are required and yields are poor to moderate. Microwaves 
dramatically reduce the heating times and also significantly increase the 
yields as shown in Scheme 3.13 [50].  
Me OEt
O O
+
Ar H
O
25% aq NH4OH
N
H
CO2EtEtO2C
Me Me
Ar
(5 equiv)
MW: 140 ºC, 10-15 min., Solvent-free, 51-92%
Convential:12 h, 15-61%
Ar = C6H5, 2-NO2C6H4,
2-CH3OC6H4, 2-ClC6H4
Scheme 3.13
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3.3.3.2 Dihydropyridopyrimidinones  
Dihydropyridopyrimidinones have been produced by ring annulations of 
aminopyrimidinones. Once again the reaction time is dramatically reduced 
and yields are much better with the solvent-free microwave conditions 
(Scheme 3.14) [51]. 
 
3.3.3.3 Dihydropyrimidines 
The Biginelli reaction is important for the preparation of 
dihydropyrimidine derivatives and excellent results are found for reactions 
carried out with microwave enhancement (Scheme 3.15) [45].  
MW: 5 min., 60-90%
Convential:12-24 h, 15-60%
R1 OEt
O O
+
H2N
O
NH2
R2 H
O HN
N
H
O
O
OEt
R1
R2
R1 = H, CH3 R2 = C6H5, 2-CH3OC6H4, 2-ClC6H4
Scheme 3.15
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3.3.3.4 Tetrazines 
The Diels-Alder reaction between aza-olefins and aza-dicarboxylic 
ester to give tetrazines is speeded-up by a factor of 1000 by microwave 
enhancement as shown in Scheme 3.16 [52]. 
Ph
N
N
R
+
N
N
N
N
N
N
Ph
CO2Et
CO2Et
R = Carbohydrate MW: 300 W, 15 min., 80-96%
Convential: 30 days
Scheme 3.16
R
COOEt
COOEt
 
3.3.4  Polycyclic six-membered rings 
3.3.4.1 Quinolines 
The Skraup synthesis has a bad reputation as it involves very messy 
conditions and gives only low yields of quinolines when carried out 
conventionally. Recently, it has been reported that microwave enhancement 
reduces the reaction time to a few minutes and allows high yields to be 
isolated (Scheme 3.17) [53]. 
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3.3.4.2 Pyrimido[1,2-a]pyrimidines 
Pyrimido[1,2-a]pyrimidines are prepared from dihydroaminopyrimidines 
and chromone-3-aldehydes as is shown in Scheme 3.18 [54].
 
Although the 
conventional reaction must proceed in refluxing ethanol, reactions are much 
faster and better yields have been obtained with microwaves. 
 
3.3.5  Nucleophilic substitutions 
3.3.5.1 Heterocyclic C-alkylations 
Nucleophilic substitution reactions can be speeded-up very 
considerably as is illustrated in Scheme 3.19a & 3.19b for a chloro-
naphthyridine derivative [55]. 
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3.3.5.2 Heterocyclic N-alkylations 
Another class of nucleophilic substitution is involved in heterocyclic N-
alkylation which we have illustrated in Scheme 3.20. This shows that 
nucleophilic substitution on the nitrogen atom of saccharin is significantly 
speeded-up by microwave irradiation [45].  
Microwave: 750 W, 2-10 min, solvent-free, 71-92%
Convential: DMF reflux, 30 min.
Scheme 3.20
S
NH
O
O
O
NaOH, RX
silica gel S
NR
O
O
O
 
3.3.5.3 Selective-alkylation 
In Scheme 3.21, the results presented indicate that selectivity is 
achieved in the N alkylation of 1,2,4-triazole under microwave conditions 
where only the N1-alkyl derivative was formed in contradistinction to the 
conventional conditions which give a considerable amount of the di-1,4-
substituted compound [56]. 
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Microwave: 90-165 ºC, 1.5-5 min, 70%
Convential: 14%; only N1,4 isolated
Scheme 3.21  
3.3.5.4 Transition metal cross-coupling 
An important type of nucleophilic substitution reactions which are 
recently much exploited are comprised of transition metal cross-coupling. A 
Suzuki coupling is shown at the top of Scheme 3.22a to give significantly 
better yield in the presence of microwave irradiation [57].
 
At the bottom of 
Scheme 3.22b another Suzuki coupling is speeded-up by a factor of 100 [58]. 
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3.3.6  Hetero-Diels-Alder reactions 
3.3.6.1 Intramolecular reactions 
We have already seen one example of a hetero-Diels-Alder reaction 
involving acyclic components. Hetero-Diels-Alder reactions involving cyclic 
components which lead to polycyclic ring systems are of great importance. An 
intramolecular example shown in Scheme 3.23 indicates that the reaction was 
accelerated by a factor of around 1000 by microwave irradiation [59]. 
 
3.3.6.2 Intermolecular reactions 
Shows two impressive examples of rate enhancement for 
intermolecular hetero-Diels-Alder reactions [59]. In the example on the Scheme 
3.24b the initial reaction is followed by elimination thus involving the 
conversion of a pyrazine derivative into a pyridine. Perhaps more impressive 
is the example in Scheme 3.24a where an autoclave is required under 
conventional conditions but which can be dispensed with when microwave 
acceleration is utilized. 
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Scheme 3.24b
 
 
 
 
 
 
 
 
Chapter-3                                                                       Pyrido[2,3-d]pyrimidine  
 
Page 103 
 
3.4 Reported Synthetic Strategies 
There are several strategies to prepare fused pyrimidine ring systems. 
The construction of a pyrimidine ring system from a 2-amino-five / six 
membered heterocyclic derivatives follows a typical reaction sequence shown 
on scheme 3.25. One of the most popular approaches to construct the 
pyrimidine ring is via the synthesis of substituted ureas and thio ureas. In a 
first step, the amino group of any heterocyclic moiety is converted into a urea 
by treatment with an isocyanides [60], potassium cyanide hydrochloride [61], or 
chlorosulfonyl isocyanides [62] and into a thiourea by reaction with an 
isothiocyanate [63], or thiophosgene and an amine [64]. The resulting ureas and 
thioureas readily undergo an intramolecular cyclization upon treatment with 
bases or acids to afford the fused pyrimidine ring systems. 
 
 
 
The synthesis of substituted pyrimidin-4-ones is well studied and can 
be categorized into four groups according to the functional groups on the 
fused heterocyclic moiety and the structures of the intermediates shown on 
scheme 3.26. 
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[1] Substituted pyrimidinones can be prepared via cyclization of diamides 
intermediates, which are generated from vic-amino carbamoyl 
benzopyrans by reaction with acylating agents such as orthoesters [65], 
acid anhydrides and acid chlorides [66], formic acid [67] and diethyl 
oxalate [68]. 
 
[2] Alternatively, the synthesis of substituted pyrimidinones can be 
achieved from vic-aminoalkoxycarbonylbenzopyrans. Amidine 
intermediates, formed by the reaction of the fused heterocyclic 
compound with amides [69], nitrites under acidic conditions [70], 
orthoesters and amines [71], undergo an intramolecular cyclization to 
afford chromeno pyrimidinones. 
 
[3] A third procedure is based on the recyclization of substituted 
oxazinones, which are generated by reaction of vic-aminocarboxylic 
acids or esters with acid chlorides or orthoesters [72]. The recyclization 
proceeds through the diamide intermediate which is generated upon 
treatment with amines [73]. 
 
[4] Vic-aminocyanoheterocyclic compounds also serve as valuable starting 
materials for the synthesis of substituted pyrimidinones. Initially, the 
oxazinimine intermediates are generated by the acylation of the amino 
group and then recyclization in the presence of an acid occurs to afford 
substituted pyrimidinones [74]. 
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3.4.1 Synthesis from 2-amino-3-cyano heterocyclic derivatives.   
Hassan [75] synthesized various differently substituted furopyrimidine 
moieties via different sets of reactants and varying reaction parameters and is 
shown below scheme 3.27. 
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The starting raw material in the above cited scheme is substituted furan 
moiety. It is also important to mention here that all the above reactions are 
carried out under the classical reaction conditions. 
 
Ladda and Bhatnagar [76] have described an efficient nimentowski 
synthesis of novel Pyrimido pyrimidinones via the intermediate preparation of 
pyrimidin-4-one as shown below scheme 3.28. Several other researchers 
have explored this chemistry in recent years and fairly good reviews and 
publications are cited in the literature [77-83]. 
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Abdalla G. Al-Sehemi et al synthesized the different heterocyclic 
compounds such as pyrido[2,3-d]pyrimidine from previous synthesized 
molecule as 2-amino-3-cyanopyromodone,which is react with formamide and 
arylidene of different aldehyde shown in scheme 3.29  [84-85].  
    
Scheme 3.29
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S. Tiwari et al synthesised Chalcones is reacted with malanonitrile and 
ammonium acetate yielded 2-amino-3-cyano-4,6-disubstituted pyridines  in 
excellent yield. 4-Amino-5,7-disubstituted pyrido [2,3-d]pyrimidine-2(1H)-
thiones , 4-amino- 5,7-disubstituted pyrido[2,3-d]pyrimidines  and 4-imino-
3,5,7-trisubstituted pyrido[2,3-d]pyrimidin-2(1H)-ones  have been synthesized 
by the condensation of compound  with thiourea, formamide and arylisocynate 
respectively(Scheme 3.30)[86]. 
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CN
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S
NH2
R2 N
R1
N
N
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R2 N
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R1 =4-CH3C6H4, 2-ClC6H4
R2 =4-OCH3C6H4, 4-ClC6H4, 4-BrC6H4,
R3 = 3-ClC6H4
Scheme 3.30
 
 
In scheme 3.31 2-Substituted-5,7-dimethyl pyrido[2,3-d]pyrimidin-
4(1H)-ones  were synthesized by oxidation of 2-substituted-5,7-dimethyl 
dihydropyrido[2,3-d ]pyrimidin-4(1H)-ones,  which were in turn prepared from 
2-amino-4,6-dimethyl nicotinamide  and substituted aromatic aldehydes. 2-
Amino-4,6-dimethyl icotinamide  was prepared from ethyl cyanoacetate via 
malonamamidine hydrochloride.Compounds were screened for antibacterial 
activity against Gram positive and Gram negative bacteria[87].  
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4-Amino-7-[4'-(2'’,5'’-dihydroxyphenyl) phenyl]-5-(substitutedphenyl) 
1(H) pyrido[2,3-d] pyrimidin-2-one, 4-amino-7-[4'-(2'’,5'’-
dihydroxyphenyl)phenyl]-5-(substituted phenyl)1(H) pyrido[2,3-d] pyrimidin-2-
thione, and 4-thioureido-7-[4'-(2'’,5'’-dihydroxy phenyl)phenyl]-5-
(substitutedphenyl) 1(H) pyrido[2,3-d]pyrimidin- 2-thione have been 
synthesized by the reaction of 2-amino-6-[4'-(2'’,5'’-dihydroxyphenyl)phenyl]-4-
(substitutedphenyl)pyridine-3-carbonitrile with urea, thiourea and ammonium 
thiocynate respectively. These compounds have been screened for their 
antibacterial and antifungal activities against different microorganisms 
(Scheme 3.32)[88]. 
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Shown in scheme 3.33 A highly efficient synthesis of novel 5-aryl-2-
phenyl-7-arylpyrido- [2,3-d]pyrimidin-4-ols, various 2-amino-4-aryl-6-
arylnicotinamides were employed as starting material to develop a cluster of 
new compounds and the key intermediate according to a known 
procedure[89,90]. Initially, when 2-amino-4,6-diphenylnicotinamide was treated 
with benzylic amine, iodine and pyridine, and aqueous tert-butyl 
hydroperoxide (TBHP) under focused microwave irradiation at 90 0C, 10 W for 
8 min, 55% of  5-aryl-2-phenyl-7-arylpyrido- [2,3-d] pyrimidin-4-ols obtain[91]. 
 
Ethyl-5-amino-8-(4-halonaphthyl)-2-methyl-4,7-dioxo- 3,4,5,6,7,8-hexa 
hydro pyrido[2,3-d]pyrimidine-6-carboxylate and Ethyl-5-amino-8-(4-
halonaphthyl)-2-amino-4,7-dioxo-3,4,5,6,7,8-hexahydro pyrido[2,3-d] 
pyrimidine-6-carboxylate derivative shown in scheme 3.34 has been 
synthesised through nucleophilic substitution reaction with the use of 
amidines, follow by 4-haloanilines and malonic acid. These novel derivative 
have been screened for antibacterial, antifungal and anti cancer activity [92].  
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The bifunctional pyrazolopyridine derivatives were prepared by the 
reaction of 2- -(2,4-dinitrophenyl)-5-methyl-2,4-dihydro-3H-pyrazol-3- one with 
benzaldehyde, malononitrile in the presence of ammonium acetate. 
Compound pyrazolo-pyrido was used as the key intermediate to prepare the 
pyrazolo-pyrido-pyrimidine derivatives through its reaction with formic acid, 
formamide-formic acid-DMF.Shown in scheme 3.35[93]. 
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In present investigation of a solvent free one pot synthesis of [indole-
pyrido[2,3-d]pyrimidines] the intermediates oxoethylidene indol were obtained 
in quantitative yields in 4-6 min by the reaction of indole-2,3-dione and 
substituted acetophenones without formation of the expected products formed 
conventionally using diethylamine as a catalyst [94]. The intermediate spiro 
[indole-dihydropyridines] are also formed in reasonable purity in quantitative 
yield under identical conditions by reaction with malononitrile and ammonium 
acetate in 5-6 min. one pot synthesis of novel spiro [indole-pyrido(2,3-
d)pyrimidines] under microwave irradiation. The synthesis gives excellent 
yields of the required products (85-89 %) in 11-13 min[95] in Scheme 3.36. 
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3.4.2 Synthesis from pyrimidine derivatives 
Three general approaches to the synthesis of pyrido[2,3-d]pyrimidines 
starting from pyrimidines are available, all of which utilized an appropriately 
substituted 4-aminopyrimidine.these pyridine ring may be formed by the 
addition of three route shown in scheme 3.37.  
 
Route I synthesis involves the reaction of 4-aminopyrimidines with 1, 3-
dicarbonyl compounds. The reaction consists of an 
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Electrophilic attack on the 5-position of the pyrimidine ring and thus 
only those pyrimidines that are activated toward electrophilic substitution [96] 
by the presence of electron donating substituents at the 2 and 4 position 
undergo cyclization.  
A wide variety of carbonyl compounds have been used in this reaction, 
for example; dialdehydes[97,98], ketoaldehydes[99], ethoxymethylene 
compounds[100,101],diketones[102,103],β-keto esters[104], malonates[105], acyl 
pyruvates[106],anaminoketones[107]. 
Route II synthesis normally involves the reaction of an active 
methylene compound containing an adjacent fuctional group capable of 
cyalization with 5-acyl or 5-ethoxycarbonyl-4-aminopyrimidines. 
4-amino-5-ethoxycarbonyl pyrimidine[108] and 2-methyl derivative[109] 
have been shown to undergo reaction with α-methylene esters, ketones, and 
nitriles to yield 5-hydroxypyrido[2,3-d]pyrimidines variously substituted at the 6 
and 7 positions. 
 Convenient synthesis was developed by Taylor and Garcia[110] who 
showed that pyrido[2,3-d]pyrimidines were obtained by the action of 
malononitrile on 5-acetyl-4-aminopyrimidine-6-(1H)-one Scheme 3.39 
 
In route III synthesis of pyrido[2,3-d]pyrimidines prepared by this route 
are not completely “aromatic” compounds. Instead they are reduced 
pyridopyrimidines, and are obtained by cyclization of an aliphatic propionyl 
derivative. 
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6-acetamido-6-ethoxycarbonyl-5,6-dihydo-2- methylthiopyrido[2,3-d] 
pyrimidine-7(8H)-one was prepared from diethyl acetamidomalonate and 2-
methylthio-4-amino-5-bromomethylpyrimidine, via the cyclization of the 
intermediate ester[111]Scheme 3.40. 
Scheme 3.40
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3.5  Present Work 
This laboratory has been actively involved in exploring the possibility of 
synthesizing novel Nitrogen containing heterocyclic molecules having 
significant biological activity. A special mention to a bountiful work done by the 
team in the class of Dihydropyridine and dihydropyrimidine synthesis under 
the conditions of atmospheric temperature and pressure as well as studying 
their biological activities against various different targets has given significant 
results. 
The pyrimidine-4-ones are structural analogues of the naturally 
occurring nucleic acids. Also the pyridone moiety has its own importance of 
being a privileged structure as it is found in various natural products and 
bioactive compounds derived from the natural products which has already 
been discussed at length in the previous chapters of this thesis. 
As a continuing endeavor to provide and promote the non conventional 
ways of synthesizing the organic compounds, microwave irradiation as a 
source of nonconventional energy has been used to synthesize all the 
compounds of this chapter. This happens to be a greener alternative as it 
reduces, time, energy as well as the other natural resources. 
As evident from the above discussions the inclusion of two bioactive 
motifs like pyridone and pyrimidine into a single carbon skeleton has never 
been achieved before. Four novel series of pyrido[2,3-d]pyrimidine   (KMK-
201 to KMK-240) have been synthesized. 
Hence, the opportunity to synthesize such interesting molecules 
exploring its biological activity was the main rationale behind the work done 
under this chapter. 
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3.6  Reaction Scheme 
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3.6.1 Physical Data Table 
Code R1 R2 M.F. 
M.W. 
(gm/
mole) 
M.P. 
(0C) 
% of 
yield
KMK-201 3-Cl-4-F-phenyl H C21H12ClFN4O2 406 >350 70
KMK-202 3-Cl-4-F-phenyl 4-OCH3 C22H14ClFN4O3 436 330-335 76 
KMK-203 3-Cl-4-F-phenyl 2-OCH3 C22H14ClFN4O3 436 325-327 62 
KMK-204 3-Cl-4-F-phenyl 4-NO2 C21H11ClFN5O4 451 303-305 78 
KMK-205 3-Cl-4-F-phenyl 2-NO2 C21H11ClFN5O4 451 320-322 65 
KMK-206 3-Cl-4-F-phenyl 4-CH3 C22H14ClFN4O2 420 342-345 72 
KMK-207 3-Cl-4-F-phenyl 4-Br C21H11BrClFN4O2 487 >350 60 
KMK-208 3-Cl-4-F-phenyl 3-Br C21H11BrClFN4O2 487 >350 62 
KMK-209 3-Cl-4-F-phenyl 4-Cl C21H11Cl2FN4O2 440 >350 71 
KMK-210 3-Cl-4-F-phenyl 3-Cl C21H11Cl2FN4O2 440 >350 79 
KMK-211 3-Cl-4-Cl-phenyl H C21H12Cl2N4O2 422 328-330 68 
KMK-212 3-Cl-4-Cl-phenyl 4-OCH3 C22H14Cl2N4O3 452 >350 80 
KMK-213 3-Cl-4-Cl-phenyl 2-OCH3 C22H14Cl2N4O3 452 333-335 73 
KMK-214 3-Cl-4-Cl-phenyl 4-NO2 C21H11Cl2N5O4 467 298-300 70 
KMK-215 3-Cl-4-Cl-phenyl 2-NO2 C21H11Cl2N5O4 467 320-325 75 
KMK-216 3-Cl-4-Cl-phenyl 4-CH3 C22H14Cl2N4O2 436 340-342 60 
KMK-217 3-Cl-4-Cl-phenyl 4-Br C21H11BrCl2N4O2 502 346-348 72 
KMK-218 3-Cl-4-Cl-phenyl 3-Br C21H11BrCl2N4O2 502 >350 64 
KMK-219 3-Cl-4-Cl-phenyl 4-Cl C21H11Cl3N4O2 456 >350 72 
KMK-220 3-Cl-4-Cl-phenyl 3-Cl C21H11Cl3N4O2 456 >350 76 
KMK-221 4-F-phenyl H C21H13FN4O2 372 338-340 80 
KMK-222 4-F-phenyl 4-OCH3 C22H15FN4O3 402 >350 71 
KMK-223 4-F-phenyl 2-OCH3 C22H15FN4O3 402 342-345 82 
KMK-224 4-F-phenyl 4-NO2 C21H12FN5O4 417 315-318 78 
KMK-225 4-F-phenyl 2-NO2 C21H12FN5O4 417 328-332 85 
KMK-226 4-F-phenyl 4-CH3 C22H15FN4O2 386 336-340 80 
KMK-227 4-F-phenyl 4-Br C21H12BrFN4O2 450 343-346 68 
KMK-228 4-F-phenyl 3-Br C21H12BrFN4O2 450 >350 72
KMK-229 4-F-phenyl 4-Cl C21H12ClFN4O2 406 350-352 74 
KMK-230 4-F-phenyl 3-Cl C21H12ClFN4O2 406 >350 69 
KMK-231 4-CH3-phenyl H C22H16N4O2 368 340-345 80 
KMK-232 4-CH3-phenyl 4-OCH3 C23H18N4O3 398 >350 77 
KMK-233 4-CH3-phenyl 2-OCH3 C23H18N4O3 398 >350 82 
KMK-234 4-CH3-phenyl 4-NO2 C22H15N5O4 413 304-308 69 
KMK-235 4-CH3-phenyl 2-NO2 C22H15N5O4 413 315-318 65 
KMK-236 4-CH3-phenyl 4-CH3 C23H18N4O2 382 330-332 75 
KMK-237 4-CH3-phenyl 4-Br C22H15BrN4O2 448 >350 68 
KMK-238 4-CH3-phenyl 3-Br C22H15BrN4O2 448 >350 77 
KMK-239 4-CH3-phenyl 4-Cl C22H15ClN4O2 402 >350 65 
KMK-240 4-CH3-phenyl 3-Cl C22H15ClN4O2 402 >350 70 
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3.6.2  Reaction Mechanism 
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3.7  Experimental 
3.7.1  Materials and Methods 
Melting points were determined in open capillary tubes and are 
uncorrected. Formation of the compounds was routinely checked by TLC on 
silica gel-G plates of 0.5 mm thickness and spots were located by iodine and 
UV. All the reactions were carried out in Samsung MW83Y Microwave Oven 
which was locally modified for carrying out chemical reactions. IR spectra 
were recorded on Shimadzu FT-IR-8400 instrument using KBr pellet method. 
Mass spectra were recorded on Shimadzu GCMS- QP-2010 model using 
Direct Injection Probe technique. 1H-NMR was determined in DMSO-d6 
solution on a Bruker Ac 400 MHz spectrometer. Elemental analysis of the all 
the synthesized compounds was carried out on Elemental Vario EL III Carlo 
Erba 1108 model and the results are in agreements with the structures 
assigned. 
 
3.7.2 Synthesis of 6-amino-1,2-dihydro-4(aryl)-2-oxo-1-(substituted 
phenyl) pyridine-3,5-dicarbonitriles 
 
The product 6-amino-1,2-dihydro-4(aryl)-2-oxo-1-(substituted phenyl) 
pyridine-3,5-dicarbonitrials synthesis from the previous chapter-2. 
3.7.3 General method for the Synthesis of 8-(3-chloro-4-flurophenyl)-2-
methyl-4,7-dioxo-5-(substituted phenyl)-3,4,7,8-tetrahydro pyrido[2,3-d] 
pyrimidine-6-carbonitrile.(KMK 201-210) 
 
0.01 M of 6-amino-1, 2-dihydro-4-(aryl)-2-oxo-1-(3-chloro-4-
fluorophenyl) pyridine-3, 5-dicarbonitriles was dissolved in 20 ml of acetic acid 
which was used as a reactant as well as solvent. A few drops of Sulfuric acid 
were introduced as the acidic catalyst to promote the reaction. The reaction 
mixture was subjected to MWI for a 20min. at low power (180 W). The 
progress of the reaction was monitored by TLC. After completion of the 
reaction, the reaction mixture was cooled to room temperature; separated 
product was filter wash with methanol and crystallized from DMF. 
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3.7.3.1 8-(3-chloro-4-fluorophenyl)-2-methyl-4,7-dioxo-5-phenyl 
3,4,7,8-tetrahydropyrido[2,3-d]pyrimidine-6- 
carbonitrile (KMK-201) 
Yield: 70%;  MP: >3500C;  MS: m/z 406;  
Elemental Analysis for C21H12ClFN4O2:   
Calculated: C, 62.00; H, 2.97; N, 13.77;%.   
Found:  C, 61.00; H, 2.87; N, 13.67;%. 
 
3.7.3.2 8-(3-chloro-4-fluorophenyl)-5-(4-methoxyphenyl)-2-methyl-
4,7-dioxo-3,4,7,8- tetrahydropyrido [2,3-d] 
pyrimidine-6-carbonitrile (KMK-202) 
Yield: 76%;  MP: 330-3350C;  MS: m/z 436;  
Elemental Analysis for C22H14ClFN4O3:   
Calculated:  C, 60.49; H, 3.23; N, 12.83;%.  
Found: C, 60.29; H, 3.13; N, 12.63;%. 
 
3.7.3.3  8-(3-chloro-4-fluorophenyl)-5-(2-methoxyphenyl)-2-methyl-
4,7-dioxo-3,4,7,8- tetrahydropyrido [2,3-d] 
pyrimidine-6-carbonitrile (KMK-203) 
Yield: 62%;  MP: 325-3270C;  MS: m/z 436;  
Elemental Analysis for C22H14ClFN4O3:    
Calculated: C, 60.49; H, 3.23; N, 12.83;%.   
Found: C, 60.39; H, 3.20; N, 12.73;%. 
 
3.7.3.4  8-(3-chloro-4-fluorophenyl)-5-(4-nitrophenyl)-2-methyl-4,7-
dioxo-3,4,7,8- tetrahydropyrido [2,3-d] pyrimidine-6-
carbonitrile (KMK-204) 
Yield: 78%;  MP: 303-3050C;  MS: m/z 451;  
Elemental Analysis for C21H11ClFN5O4:   
Calculated: C, 55.83; H, 2.45; N, 15.50;%.   
Found: C, 55.73; H, 2.41; N, 15.40;%. 
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3.7.3.5  8-(3-chloro-4-fluorophenyl)-5-(2-nitrophenyl)-2-methyl-4,7-
dioxo-3,4,7,8- tetrahydropyrido [2,3-d] pyrimidine-
6-carbonitrile (KMK-205) 
Yield: 65%;  MP: 320-3220C;  MS: m/z 451;  
Elemental Analysis for C21H11ClFN5O4:   
Calculated: C, 55.83; H, 2.45; N, 15.50;%.  
Found: C, 55.71; H, 2.31; N, 15.44;%. 
 
3.7.3.6  8-(3-chloro-4-fluorophenyl)-2-methyl-4,7-dioxo-5-(p-tolyl)-
3,4,7,8- tetrahydropyrido [2,3-d] pyrimidine-6-
carbonitrile (KMK-206) 
Yield: 72%;  MP: 342-3450C;  MS: m/z 420;  
Elemental Analysis for C22H14ClFN4O2:   
Calculated: C, 62.79; H, 3.35; N, 13.31;%.   
Found: C, 61.31; H, 3.18; N, 13.17; %. 
 
3.7.3.7  5-(4-bromophenyl)-8-(3-chloro-4-fluorophenyl)-2-methyl-4,7 
-dioxo-3,4,7,8- tetrahydropyrido [2,3-d] pyrimidine-
6-carbonitrile (KMK-207) 
Yield: 60%;  MP: >3500C;  MS: m/z 487;  
Elemental Analysis for C21H11BrClFN4O2:   
Calculated:  C, 51.93; H, 2.28; N, 11.54;%.   
Found: C, 51.91; H, 2.25; N, 11.52;%. 
 
3.7.3.8  5-(3-bromophenyl)-8-(3-chloro-4-fluorophenyl)-2-methyl-4,7 
-dioxo-3,4,7,8- tetrahydropyrido [2,3-d] pyrimidine-
6-carbonitrile (KMK-208) 
Yield: 62%;  MP: >3500C;  MS: m/z 487;  
Elemental Analysis for C21H11BrClFN4O2:   
Calculated: C, 51.93; H, 2.28; N, 11.54; %.  
Found: C, 51.81; H, 2.15; N, 11.51; %. 
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3.7.3.9  8-(3-chloro-4-fluorophenyl)-5-(4-chlorophenyl)-2-methyl-4,7-
dioxo-3,4,7,8-tetrahydropyrido [2,3-d] pyrimidine-6-
carbonitrile (KMK-209) 
Yield: 71%;  MP: >3500C;  MS: m/z 440;  
Elemental Analysis for C21H11Cl2FN4O2:   
Calculated:  C, 57.16; H, 2.51; N, 12.70; %. 
Found: C, 57.06; H, 2.50; N, 12.63; %. 
 
3.7.3.10  8-(3-chloro-4-fluorophenyl)-5-(3-chlorophenyl)-2-methyl-4,7-
dioxo-3,4,7,8- tetrahydropyrido [2,3-d] pyrimidine-6-
carbonitrile (KMK-210) 
Yield: 79%;  MP: >3500C;  MS: m/z 440;  
Elemental Analysis for C21H11Cl2FN4O2:   
Calculated: C, 57.16; H, 2.51; N, 12.70; %.   
Found: C, 57.08; H, 2.48; N, 12.69; %. 
 
 
 
3.7.4 General method for the Synthesis of 8-(3,4-dichlorophenyl)-2-
methyl-4,7-dioxo-5-(substituted phenyl)-3,4,7,8-tetrahydro pyrido[2,3-d] 
pyrimidine-6-carbonitrile.(KMK 211-220) 
 
0.01 M of 6-amino-1, 2-dihydro-4-(aryl)-2-oxo-1-(3,4-dichlorophenyl) 
pyridine-3, 5-dicarbonitriles was dissolved in 20 ml of acetic acid which was 
used as a reactant as well as solvent. A few drops of Sulfuric acid were 
introduced as the acidic catalyst to promote the reaction. The reaction mixture 
was subjected to MWI for a 25min. at low power (180 W). The progress of the 
reaction was monitored by TLC. After  completion of the reaction, the reaction 
mixture was cooled to room temperature, separated product was filter wash 
with methanol and crystallized from DMF. 
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3.7.4.1 8-(3,4-dichlorophenyl)-2-methyl-4,7-dioxo-5-phenyl 3,4,7,8- 
tetrahydropyrido[2,3-d]pyrimidine-6-carbonitrile    
(KMK-211) 
Yield: 68%;  MP: 328-3300C;  MS: m/z 422;  
Elemental Analysis for C21H12Cl2N4O2:   
Calculated: C, 59.59; H, 2.86; N, 13.24; %.  
Found:  C, 59.49; H, 2.81; N, 13.22; %. 
 
 3.7.4.2 8-(3,4-dichlorophenyl)-5-(4-methoxyphenyl)-2-methyl-4,7-
dioxo-3,4,7,8- tetrahydropyrido [2,3-d] pyrimidine-
6-carbonitrile (KMK-212) 
Yield: 80%;  MP: >3500C;  MS: m/z 452;  
Elemental Analysis for C22H14Cl2N4O3:   
Calculated: C, 58.29; H, 3.11; N, 12.36; %  
Found: C, 58.24; H, 3.05; N, 12.30;  %. 
 
3.7.4.3 8-(3,4-dichlorophenyl)-5-(2-methoxyphenyl)-2-methyl-4,7-
dioxo-3,4,7,8- tetrahydropyrido [2,3-d] pyrimidine-
6-carbonitrile (KMK-213) 
Yield: 73%;  MP: 333-3350C;  MS: m/z 452;  
Elemental Analysis for C22H14Cl2N4O3:   
Calculated: C, 58.29; H, 3.11; N, 12.36;  
Found: C, 58.20; H, 3.09; N, 12.33;  %. 
 
3.7.4.4 8-(3,4-dichlorophenyl)-2-methyl-5-(4-nitrophenyl) -4,7-dioxo-
3,4,7,8- tetrahydropyrido [2,3-d] pyrimidine-6-
carbonitrile (KMK-214) 
Yield: 70%;  MP: 298-3000C;  MS: m/z 467;  
Elemental Analysis for C21H11Cl2N5O4:   
Calculated: C, 53.87; H, 2.37; N, 14.96; %.   
Found: C, 53.80; H, 2.33; N, 14.91; %. 
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3.7.4.5 8-(3,4-dichlorophenyl)-2-methyl-5-(2-nitrophenyl) -4,7-dioxo-
3,4,7,8- tetrahydropyrido [2,3-d] pyrimidine-6-
carbonitrile (KMK-215) 
Yield: 75%;  MP: 320-3250C;  MS: m/z 467;  
Elemental Analysis for C21H11Cl2N5O4:   
Calculated:  C, 53.87; H, 2.37; N, 14.96; %. 
Found: C, 53.85; H, 2.31; N, 14.90; %. 
 
 3.7.4.6  8-(3,4-dichlorophenyl)-2-methyl-4,7-dioxo-5-(p-tolyl)-3,4,7,8- 
tetrahydropyrido [2,3-d] pyrimidine-6-carbonitrile 
(KMK-216) 
Yield: 60%;  MP: 340-3420C;  MS: m/z 436;  
Elemental Analysis for C22H14Cl2N4O2:   
Calculated:  C, 60.43; H, 3.23; N, 12.81; %.  
Found: C, 60.40; H, 3.21; N, 12.75; %. 
 
3.7.4.7  5-(4-bromopnenyl)-8-(3,4-dichlorophenyl) -2-methyl-4,7-
dioxo-3,4,7,8- tetrahydropyrido [2,3-d] pyrimidine-6-
carbonitrile (KMK-217) 
Yield: 72%;  MP: 346-3480C;  MS: m/z 502;  
Elemental Analysis for C21H11BrCl2N4O2:   
Calculated: C, 50.23; H, 2.21; N, 11.16; %. 
Found: C, 50.20; H, 2.18; N, 11.10; %. 
 
3.7.4.8 5-(3-bromopnenyl)-8-(3,4-dichlorophenyl) -2-methyl-4,7-
dioxo-3,4,7,8- tetrahydropyrido [2,3-d] pyrimidine-6-
carbonitrile (KMK-218) 
Yield: 64%;  MP: >3500C;  MS: m/z 502;  
Elemental Analysis for C21H11BrCl2N4O2:   
Calculated:  C, 50.23; H, 2.21; N, 11.16; %.  
Found: C, 50.18; H, 2.15; N, 11.11; %. 
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3.7.4.9 5-(4-chloropnenyl)-8-(3,4-dichlorophenyl) -2-methyl-4,7-
dioxo-3,4,7,8- tetrahydropyrido [2,3-d] pyrimidine-
6-carbonitrile (KMK-219) 
Yield: 72%;  MP: >3500C;  MS: m/z 456;  
Elemental Analysis for C21H11Cl3N4O2:   
Calculated:  C, 55.11; H, 2.42; N, 12.24; %.  
Found:  C, 55.10; H, 2.41; N, 12.20; %. 
 
3.7.4.10 5-(3-chloropnenyl)-8-(3,4-dichlorophenyl) -2-methyl-4,7-
dioxo-3,4,7,8- tetrahydropyrido [2,3-d] pyrimidine-6-
carbonitrile (KMK-220) 
Yield: 76%;  MP: >3500C;  MS: m/z 456;  
Elemental Analysis for C21H11Cl3N4O2:   
C, 55.11; H, 2.42; N, 12.24; %. 
Found:  C, 55.07; H, 2.36; N, 12.18; %. 
 
 
 
 
 
3.7.5 General method for the Synthesis of 8-(4-fluorophenyl)-2-methyl-
4,7-dioxo-5-(substituted phenyl)-3,4,7,8-tetrahydro pyrido[2,3-d] 
pyrimidine-6-carbonitrile.(KMK 221-230) 
 
0.01 M of 6-amino-1, 2-dihydro-4-(aryl)-2-oxo-1-(4-fluorophenyl) 
pyridine-3, 5-dicarbonitriles was dissolved in 20 ml of acetic acid which was 
used as a reactant as well as solvent. A few drops of Sulfuric acid were 
introduced as the acidic catalyst to promote the reaction. The reaction mixture 
was subjected to MWI for a 15min. at low power (180 W). The progress of the 
reaction was monitored by TLC. After completion of the reaction, the reaction 
mixture was cooled to room temperature; separated product was filter wash 
with methanol and crystallized from DMF. 
 
 
Chapter-3                                                                       Pyrido[2,3-d]pyrimidine  
 
Page 127 
 
 3.7.5.1 8-(4-fluorophenyl)-2-methyl-4,7-dioxo-5-phenyl 3,4,7,8- 
tetrahydropyrido[2,3-d]pyrimidine-6-carbonitrile 
(KMK-221) 
 Yield: 80%;  MP: 338-3400C;  MS: m/z  372;  
Elemental Analysis for C21H13FN4O2:   
Calculated: C, 67.74; H, 3.52; N, 15.05; %.  
Found: C, 67.70; H, 3.48; N, 15.00; %. 
 
 3.7.5.2 8-(4-fluorophenyl)-5-(4-methoxyphenyl)-2-methyl-4,7-dioxo-
3,4,7,8- tetrahydropyrido[2,3-d]pyrimidine-6-
carbonitrile (KMK-222)  
Yield: 71%;  MP: >3500C;  MS: m/z 402;  
Elemental Analysis for C22H15FN4O3:   
Calculated: C, 65.67; H, 3.76; N, 13.92; %. 
Found: C, 65.62; H, 3.71; N, 13.82; %. 
 
3.7.5.3 8-(4-fluorophenyl)-5-(2-methoxyphenyl)-2-methyl-4,7-dioxo-
3,4,7,8- tetrahydropyrido[2,3-d]pyrimidine-6-
carbonitrile (KMK-223)  
Yield: 82%;  MP: 342-3450C;  MS: m/z 402;  
Elemental Analysis for C22H15FN4O3:   
Calculated: C, 65.67; H, 3.76; N, 13.92; %. 
Found: C, 65.60; H, 3.68; N, 13.80; %. 
 
3.7.5.4 8-(4-fluorophenyl)-2-methyl-5-(4-nitrophenyl)-4,7-dioxo-3,4, 
7,8-tetrahydropyrido[2,3-d]pyrimidine-6-carbonitrile 
(KMK-224)  
Yield: 78%;  MP: 315-3180C;  MS: m/z 417;  
Elemental Analysis for C21H12FN5O4:   
Calculated:  C, 60.43; H, 2.90; N, 16.78; %.  
Found:  C, 60.38; H, 2.89; N, 16.72; %. 
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3.7.5.5 8-(4-fluorophenyl)-2-methyl-5-(2-nitrophenyl)-4,7-dioxo-3,4, 
7,8-tetrahydropyrido[2,3-d]pyrimidine-6-carbonitrile 
(KMK-225)  
Yield: 85%;  MP: 328-3320C;  MS: m/z 417;  
Elemental Analysis for C21H12FN5O4:   
Calculated: C, 60.43; H, 2.90; N, 16.78; %.  
Found:  C, 60.36; H, 2.87; N, 16.70; %. 
 
3.7.5.6  8-(4-fluorophenyl)-2-methyl-4,7-dioxo-5-(p-tolyl)-3,4,7,8- 
tetrahydropyrido [2,3-d] pyrimidine-6-carbonitrile 
(KMK-226)  
Yield: 80%;  MP: 336-3400C;  MS: m/z 386;  
Elemental Analysis for C22H15FN4O2:   
Calculated: C, 68.39; H, 3.91; N, 14.50; %. 
Found: C, 68.32; H, 3.88; N, 14.41; %. 
 
 3.7.5.7  5-(4-bromopnenyl)-8-(4-fluorophenyl)-2-methyl-4,7-dioxo-
3,4,7,8- tetrahydropyrido [2,3-d] pyrimidine-6-
carbonitrile (KMK-227)  
Yield: 68%;  MP: 343-3460C; MS: m/z 450;  
Elemental Analysis for C21H12BrFN4O2:   
Calculated:  C, 55.89; H, 2.68; N, 12.42; %. 
Found:  C, 55.82; H, 2.61; N, 12.41; %. 
 
 3.7.5.8  5-(3-bromopnenyl)-8-(4-fluorophenyl)-2-methyl-4,7-dioxo-
3,4,7,8- tetrahydropyrido [2,3-d] pyrimidine-6-
carbonitrile (KMK-228)  
Yield: 72%;  MP: >3500C;   MS: m/z 450;  
Elemental Analysis for C21H12BrFN4O2:   
Calculated:  C, 55.89; H, 2.68; N, 12.42; %.  
Found:  C, 55.85; H, 2.60; N, 12.40;%. 
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3.7.5.9  5-(4-chloropnenyl)-8-(4-fluorophenyl)-2-methyl-4,7-dioxo-
3,4,7,8- tetrahydropyrido [2,3-d] pyrimidine-6-
carbonitrile (KMK-229)  
Yield: 74%;  MP: 350-3520C;  MS: m/z 406;  
Elemental Analysis for C21H12ClFN4O2:   
Calculated: C, 62.00; H, 2.97; N, 13.77; %.  
Found: C, 61.82; H, 2.90; N, 13.72; %. 
 
 
3.7.5.10  5-(3-chloropnenyl)-8-(4-fluorophenyl)-2-methyl-4,7-dioxo-
3,4,7,8- tetrahydropyrido [2,3-d] pyrimidine-6-
carbonitrile (KMK-230)  
Yield: 69%;  MP: >3500C;  MS: m/z 406;  
Elemental Analysis for C21H12ClFN4O2:   
Calculated: C, 62.00; H, 2.97; N, 13.77; %. 
Found: C, 61.92; H, 2.93; N, 13.70; %. 
 
 
 
3.7.6 General method for the Synthesis of 8-(p-tolyl)-2-methyl-4,7-dioxo-
5-(substituted phenyl)-3,4,7,8-tetrahydro pyrido[2,3-d] pyrimidine-6-
carbonitrile.(KMK 231-240) 
 
0.01 M of 6-amino-1, 2-dihydro-4-(aryl)-2-oxo-1-(p-tolyl) pyridine-3, 5-
dicarbonitriles was dissolved in 20 ml of acetic acid which was used as a 
reactant as well as solvent. A few drops of Sulfuric acid were introduced as 
the acidic catalyst to promote the reaction. The reaction mixture was 
subjected to MWI for a 15min. at low power (180 W). The progress of the 
reaction was monitored by TLC. After  completion of the reaction, the reaction 
mixture was cooled to room temperature, separated product was filter wash 
with methanol and crystallized from DMF. 
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  3.7.6.1 2-methyl-4,7-dioxo-5-phenyl-8-(p-tolyl)-3,4,7,8-tetrahydro 
pyrido[2,3-d]pyrimidine-6-carbonitrile (KMK-231) 
Yield: 80%;  MP: 340-3450C;  MS: m/z 368;  
Elemental Analysis for C22H16N4O2:   
Calculated: C, 71.73; H, 4.38; N, 15.21; %.  
Found: C, 71.71; H, 4.32; N, 15.20; %. 
 
 
3.7.6.2 5-(4-methoxyphenyl)-2-methyl-4,7-dioxo-8-(p-tolyl)-3,4,7,8-
tetrahydro pyrido[2,3-d]pyrimidine-6-carbonitrile 
(KMK-232)  
Yield: 77%;  MP: >3500C;  MS: m/z 398;  
Elemental Analysis for C23H18N4O3:   
Calculated: C, 69.34; H, 4.55; N, 14.06; %.  
Found: C, 69.30; H, 4.51; N, 14.00; %. 
 
 
3.7.6.3 5-(2-methoxyphenyl)-2-methyl-4,7-dioxo-8-(p-tolyl)-3,4,7,8-
tetrahydro pyrido[2,3-d]pyrimidine-6-carbonitrile 
(KMK-233)  
Yield: 82%;  MP: >3500C;  MS: m/z 398;  
Elemental Analysis for C23H18N4O3:   
Calculated: C, 69.34; H, 4.55; N, 14.06; %. 
Found: C, 69.32; H, 4.46; N, 13.80; %. 
 
 
3.7.6.4 2-methyl-5-(4-nitrophenyl)-4,7-dioxo-8-(p-tolyl)-3,4,7,8-tetra 
hydro pyrido[2,3-d]pyrimidine-6-carbonitrile (KMK-
234)  
Yield: 69%;  MP: 304-3080C;  MS: m/z 413;  
Elemental Analysis for C22H15N5O4:   
Calculated:  C, 63.92; H, 3.66; N, 16.94; %. 
 Found: C, 63.88; H, 3.61; N, 16.84; %. 
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3.7.6.5 2-methyl-5-(2-nitrophenyl)-4,7-dioxo-8-(p-tolyl)-3,4,7,8-tetra 
hydro pyrido[2,3-d]pyrimidine-6-carbonitrile (KMK-
235)  
Yield: 65%;  MP: 315-3180C;  MS: m/z 413;  
Elemental Analysis for C22H15N5O4:   
Calculated: C, 63.92; H, 3.66; N, 16.94; %. 
Found: C, 63.84; H, 3.60; N, 16.86; %. 
 
3.7.6.6 2-methyl-4,7-dioxo-5,8-di-p-tolyl-3,4,7,8-tetrahydro pyrido 
[2,3-d]pyrimidine-6-carbonitrile (KMK-236)  
Yield: 75%;  MP: 330-3320C;  MS: m/z 382;  
Elemental Analysis for C23H18N4O2:   
Calculated: C, 72.24; H, 4.74; N, 14.65;%. 
Found: C, 72.21; H, 4.73; N, 14.62; %. 
 
 
 3.7.6.7  5-(4-bromophenyl)-2-methyl-4,7-dioxo-8-(p-tolyl)-3,4,7,8- 
tetrahydropyrido [2,3-d] pyrimidine-6-carbonitrile 
(KMK-237)  
Yield: 68%;  MP: >3500C;  MS: m/z 448;  
Elemental Analysis for C22H15BrN4O2:   
Calculated: C, 59.08; H, 3.38; N, 12.53; %. 
Found: C, 58.88; H, 3.32; N, 12.48; %. 
 
3.7.6.8  5-(3-bromophenyl)-2-methyl-4,7-dioxo-8-(p-tolyl)-3,4,7,8- 
tetrahydropyrido [2,3-d] pyrimidine-6-carbonitrile 
(KMK-238)  
Yield: 77%;  MP: >3500C; MS: m/z 448;  
Elemental Analysis for C22H15BrN4O2:   
Calculated: C, 59.08; H, 3.38; N, 12.53; %.  
Found: C, 58.98; H, 3.30; N, 12.46; %. 
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3.7.6.9  5-(4-chlorophenyl)-2-methyl-4,7-dioxo-8-(p-tolyl)-3,4,7,8- 
tetrahydropyrido [2,3-d] pyrimidine-6-carbonitrile 
(KMK-239)  
Yield: 65%;  MP: >3500C;  MS: m/z 402;  
Elemental Analysis for C22H15ClN4O2:   
Calculated:  C, 65.59; H, 3.75 N, 13.91; %. 
Found: :  C, 65.53; H, 3.71 N, 13.88; %. 
 
3.7.6.10  5-(3-chlorophenyl)-2-methyl-4,7-dioxo-8-(p-tolyl)-3,4,7,8- 
tetrahydropyrido [2,3-d] pyrimidine-6-carbonitrile 
(KMK-240)  
Yield: 70%;  MP: >3500C;  MS: m/z 402;  
Elemental Analysis for C22H15ClN4O2:   
Calculated: C, 65.59; H, 3.75 N, 13.91; %. 
Found:  C, 65.50; H, 3.68 N, 13.84; %. 
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3.8  Spectral Discussion 
3.8.1  IR Spectral Study 
IR spectra were recorded on Shimadzu FT-IR-8400 model using KBr 
pellet method. Various functional groups present in molecule were identified 
by characteristic frequency obtained for them. For Pyrido[2,3-d]pyrimidine 
(KMK-201 to 240), confirmatory bands for Cyclic amide (-NH), carbonyl (C=O) 
and nitrile (C≡N) stretching band was observed at 3250-3500 cm-1, 1630-1700 
cm-1 and 2200-2230 cm-1 respectively. Another characteristic band for N-H 
deformation and C-N stretching were observed at 1500-1600 cm-1 and 1200-
1360 cm-1 respectively, which suggested the formation of pyridopyrimidine 
ring. 
3.8.2  1H NMR Spectral Study 
1H NMR spectra were recorded in DMSO-d6 solution on a Bruker Ac 
400 MHz spectrometer using TMS as an internal standard. Number of protons 
and their chemical shifts were found to support the structure of the 
synthesized compounds. 
1H NMR spectra confirmed the structures of Pyrido[2,3-d]pyrimidine 
(KMK-201 to 240), on the basis of following signals: singlet for Cyclic amide 
group proton was observed at 12.50-12.70 δ ppm. The aromatic ring protons 
and J value were found to be in accordance with substitution pattern on 
phenyl ring.  
3.8.3  Mass Spectral Study 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model 
using Direct Injection Probe technique. Systematic fragmentation pattern was 
observed in mass spectral analysis. Molecular ion peak was observed in 
agreement with molecular weight of respective compound. Mass 
fragmentation pattern for a representative compound of each series is 
depicted below. 
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IR spectra of KMK-202 
 
Sr. No. Frequency (cm-1) Vibration Mode 
1 3144 N-H Streching of amide 
2 2943 C-H Streching of aromatic ring 
3 2868 C-H Streching of CH3 group 
4 2223 C≡N Streching of nitrial group 
5 1684 C=O Steching of pyrido & Pyrimidine ring 
6 1596 C=C Steching of aromatic ring 
7 1494 C=N Steching of Pyrimidine ring 
8 1249 C-F Streching 
9 1171 C-O-C asymmetrical stretching of ether linkage 
10 1030 C-H in plane bending of aromatic ring 
11 815 out of plane bending for disubstituted aromatic ring 
12 707 C-Cl Streching 
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1H-NMR spectra of KMK-202 
 
 
 
Signal 
No. 
 
 
Signal Position 
δppm 
 
 
Relative No. 
of Protons 
 
Multiplicity 
 
 
Inference 
 
1 2.19 3 Singlet CH3(a) 
2 3.84 3 Singlet OCH3(b) 
3 7.01-7.04 2 doublet Ar-CH(c-c’) 
4 7.28-7.31 2 doublet Ar-CH(d-d’) 
5 7.60 1 Singlet Ar-CH(g) 
6 7.57-7.63 1 triplet Ar-CH(f) 
7 7.69-7.72 2 doublet Ar-CH(e) 
8 12.7 1 Singlet NH(h) 
 
 
 
Chapter-3                                                                       Pyrido[2,3-d]pyrimidine  
 
Page 136 
 
Expanded 1H-NMR spectra of KMK-202 
 
 
Mass spectra of KMK-202 
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Mass fragmentation pattern for KMK-202 
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IR spectra of KMK-212 
 
Sr. 
No. 
Frequency 
(cm-1) Vibration Mode 
1 3173 N-H Streching of amide 
2 2942 C-H Streching of aromatic ring 
3 2848 C-H Streching of CH3 group 
4 2223 C≡N Streching of nitrial group 
5 1685 C=O Steching of pyrido & Pyrimidine ring 
6 1595 C=C Steching of aromatic ring 
7 1480 C=N Steching of Pyrimidine ring 
8 1242 C-N Streching 
9 1170 C-O-C asymmetrical stretching of ether linkage 
10 1031 C-O-C symmetrical stretching of ether linkage 
11 814 Out of plane bending for disubstituted aromatic ring 
12 733 C-Cl Streching 
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1H-NMR spectra of KMK-212 
 
 
Signal 
No. 
 
Signal Position 
δppm 
Relative No. 
of Protons 
 
Multiplicity 
 
 
Inference 
 
1 2.19 3 Singlet CH3(a) 
2 3.84 3 Singlet OCH3(b) 
3 7.01-7.04 2 doublet Ar-CH(c-c’) 
4 7.28-7.31 2 doublet Ar-CH(d-d’) 
5 7.38-7.41 1 doublet Ar-CH(f) 
6 7.76 1 Singlet Ar-CH(g) 
7 7.81-7.84 2 doublet Ar-CH(e) 
8 12.7 1 Singlet NH(h) 
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Expanded 1H-NMR spectra of KMK-212 
 
 
Mass spectra of KMK-212 
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Mass fragmentation pattern for KMK-212 
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IR spectra of KMK-222 
 
Sr. No. Frequency (cm-1) Vibration Mode 
1 3068 N-H Streching of amide 
2 2944 C-H Streching of aromatic ring 
3 2816 C-H Streching of CH3 group 
4 2226 C≡N Streching of nitrial group 
5 1684 C=O Steching of pyrido & Pyrimidine ring 
6 1597 C=C Steching of aromatic ring 
7 1479 C=N Steching of Pyrimidine ring 
8 1243 C-F Streching 
9 1166 C-O-C asymmetrical stretching of ether linkage 
10 1107 C-O-C symmetrical stretching of ether linkage 
11 1027 C-H out of  plane bending of aromatic ring 
12 831 out of plane bending for disubstituted aromatic ring 
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1H-NMR spectra of KMK-222 
 
 
Signal 
No. 
 
Signal Position 
δppm 
Relative No. 
of Protons 
 
Multiplicity 
 
 
Inference 
 
1 2.16 3 Singlet CH3(a) 
2 3.83 3 Singlet OCH3(b) 
3 7.01-7.03 2 doublet Ar-CH(c-c’) 
4 7.29-7.38 6 Multiplate Ar-CH(dd’,ee’,ff’) 
5 12.6 1 Singlet NH(g) 
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Expanded 1H-NMR spectra of KMK-222 
 
 
Mass spectra of KMK-222 
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Mass fragmentation pattern for KMK-232 
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IR spectra of KMK-240 
 
Sr. 
No. 
Frequency 
(cm-1) Vibration Mode 
1 3149 N-H Streching of amide 
2 2988 C-H Streching of aromatic ring 
3 2868 C-H Streching of CH3 group 
4 2220 C≡N Streching of nitrial group 
5 1661 C=O Steching of pyrido & Pyrimidine ring 
6 1599 C=C Steching of aromatic ring 
7 1496 C=N Steching of Pyrimidine ring 
8 1225 C-N Streching 
9 1170 C-H in plane defomation 
10 886 out of plane bending for disubstituted aromatic ring 
11 785 C-Cl Streching 
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1H-NMR spectra of KMK-240 
 
 
Signal 
No. 
 
Signal Position 
δppm 
Relative No. 
of Protons 
 
Multiplicity 
 
 
Inference 
 
1 2.17 3 Singlet CH3(a) 
2 2.39 3 Singlet CH3(b) 
3 7.13-7.18 2 doublet Ar-CH(c-c’) 
4 7.28-7.31 3 doublet Ar-CH(f,g,h) 
5 7.45 1 Singlet Ar-CH(e) 
6 7.51-7.53 2 doublet Ar-CH(d-d’) 
7 12.6 1 Singlet NH(i) 
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Expanded 1H-NMR spectra of KMK-240 
 
 
Mass spectra of KMK-240 
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Mass fragmentation pattern for KMK-240 
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3.9  Biological Evaluation 
3.9.1  Antimicrobial Evaluation 
All the synthesized compounds (KMK-201 to KMK-240) were tested for 
their antibacterial and antifungal activity (MIC) in vitro by broth dilution method 
[112, 113] with two Gram-positive bacteria Staphylococcus aureus MTCC-96, 
Streptococcus pyogenes MTCC 443, two Gram-negative bacteria Escherichia 
coli MTCC 442, Pseudomonas aeruginosa MTCC 441 and three fungal 
strains Candida albicans MTCC 227, Aspergillus Niger MTCC 282, 
Aspergillus clavatus MTCC 1323 taking ampicillin, chloramphenicol, 
ciprofloxacin, norfloxacin, nystatin, and greseofulvin as standard drugs. The 
standard strains were procured from the Microbial Type Culture Collection 
(MTCC) and Gene Bank, Institute of Microbial Technology, Chandigarh, India.  
 The minimal inhibitory concentration (MIC) values for all the newly 
synthesized compounds, defined as the lowest concentration of the 
compound preventing the visible growth, were determined by using 
microdilution broth method according to NCCLS standards [112]. Serial 
dilutions of the test compounds and reference drugs were prepared in 
Muellere-Hinton agar. Drugs (10 mg) were dissolved in dimethylsulfoxide 
(DMSO, 1 mL). Further progressive dilutions with melted Muellere-Hinton agar 
were performed to obtain the required concentrations. In primary screening 
1000 μg mL-1, 500 μg mL-1 and 250 μg mL-1 concentrations of the synthesized 
drugs were taken. The active synthesized drugs found in this primary 
screening were further tested in a second set of dilution at 200 μg mL-1, 100 
μg mL-1, 50 μg mL-1, 25 μg mL-1, 12.5 μg mL-1, and 6.25 μg mL-1 
concentration against all microorganisms. The tubes were inoculated with 108 
cfu mL-1 (colony forming unit/mL) and incubated at 37 ºC for 24 h. The MIC 
was the lowest concentration of the tested compound that yields no visible 
growth (turbidity) on the plate. To ensure that the solvent had no effect on the 
bacterial growth, a control was performed with the test medium supplemented 
with DMSO at the same dilutions as used in the experiments and it was 
observed that DMSO had no effect on the microorganisms in the 
concentrations studied. 
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Antibacterial and antifungal activity of synthesized compounds KMK-
101 to 140 
Code 
Antibacterial Activity Antifungal Activity 
Minimal Bactericidal 
Concentration μg/ml Minimal Fungicidal 
Concentration μg/ml Gram +ve 
Bacteria 
Gram –ve 
Bacteria 
S.a. S.p. E.c. P.a. C.a. A.n. A.c. 
KMK-201 100 250 200 200 500 >1000 >1000 
KMK-202 200 200 100 100 >1000 >1000 >1000 
KMK-203 250 250 100 250 500 1000 500 
KMK-204 500 500 200 200 1000 500 1000 
KMK-205 250 500 250 500 >1000 1000 1000 
KMK-206 100 250 200 200 500 >1000 >1000 
KMK-207 500 500 62.5 200 >1000 1000 1000 
KMK-208 200 250 200 100 250 1000 1000 
KMK-209 100 62.5 250 250 >1000 100 1000 
KMK-210 100 500 62.5 250 500 >1000 1000 
KMK-211 200 500 250 250 >1000 >1000 >1000 
KMK-212 200 250 200 100 500 1000 1000 
KMK-213 250 250 100 250 500 1000 500 
KMK-214 500 500 200 200 1000 500 1000 
KMK-215 100 62.5 250 250 >1000 500 1000 
KMK-216 100 250 200 200 500 >1000 >1000 
KMK-217 100 62.5 250 250 >1000 100 1000 
KMK-218 100 500 62.5 250 250 >1000 1000 
KMK-219 200 250 200 100 250 1000 1000 
KMK-220 100 62.5 250 250 >1000 500 1000 
KMK-221 200 100 100 100 250 1000 250 
KMK-222 100 200 62.5 200 500 100 >1000 
KMK-223 250 250 250 500 1000 500 >1000 
KMK-224 500 500 250 500 500 >1000 1000 
KMK-225 500 500 200 500 >1000 >1000 >1000 
KMK-226 250 62.5 250 500 1000 500 500 
KMK-227 500 500 250 250 250 100 100 
KMK-228 500 500 100 250 250 1000 250 
KMK-229 500 200 100 250 500 500 >1000 
KMK-230 100 200 500 500 250 >1000 >1000 
KMK-231 500 62.5 250 250 250 200 100 
KMK-232 200 500 250 500 1000 500 >1000 
KMK-233 250 500 500 500 1000 500 500 
KMK-234 500 500 250 500 >1000 >1000 >1000 
KMK-235 250 500 500 500 250 >1000 >1000 
KMK-236 500 250 100 100 500 >1000 250 
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KMK-237 100 250 100 250 500 100 >1000 
KMK-238 200 100 100 500 500 1000 200 
KMK-239 500 250 250 500 500 >1000 1000 
KMK-240 500 500 1000 1000 500 1000 1000 
 
Minimal Inhibition Concentration 
 
Standard Drugs S.aureus S.pyogenus E.coli P.aeruginosa
(microgramme/ml) 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
 
Minimal Fungicidal Concentration 
 
Standard Drugs C.Albicans  A.Niger  A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
Greseofulvin 500 100 100 
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Chapter 4 
Synthesis and Biological Evaluation 
of Benzopyran 
 
 
 
4.1 Introduction 
A search of chemical abstracts revealed the 2,2-Dimethyl- 2H-
benzopyran moiety to be present in more than 4000 compounds including 
natural products and designed structures. 
The relatively high incidence of this benzopyran unit in natural products 
is partially attributable to the numerous prenylation and cyclization reactions in 
many polyketide biosynthesis pathways. Examining the characteristics of 
many biologically active, natural products like benzopyran compounds, 
reveals their diverse structural properties, and more importantly, their wide 
ranging biological actions, suggesting that derivatives of the benzopyran motif 
may be capable of interacting with a variety of cellular targets. In addition, the 
fact that many of the structures are active in cell-based assays suggested that 
derivatives of the benzopyran unit remain sufficiently lipophilic to cross cell 
membranes, a key feature of any biologically relevant small molecule library [1-
3]. 
Chromene derivatives are an important class of compounds, widely 
present in plants, including edible vegetables and fruits [4]. Numerous 
bioactive natural products have been identified, and the presence of the 
chromene-based structure has been associated with the capacity to prevent 
disease [5]. Synthetic analogues have been developed over the years, some of 
them displaying remarkable effects as pharmaceuticals [6], including antifungal 
[7], anti-microbial [8], molluscidial [9], anticoagulant, spasmolytic, diuretic, 
anticancer and antianaphylactic characteristics [10]. Moreover, nitrogen-
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containing heterocycles [11, 12] are also of broad pharmaceutical interest and 
significance, which justifies our continuing efforts in designing novel 
heterocyclic molecules of biological importance. 
Also, the development of environmentally benign, efficient and 
economical methods for the synthesis of biologically interesting compounds 
remains a significant challenge in synthetic chemistry. The chemical industry 
is one of the major contributors to environment pollution, owing to the use of 
hazardous chemicals and in particular large amounts of flammable, volatile 
and often toxic organic solvents. Green chemistry emphasizes the need for 
environmentally clean synthesis, which involves improvement in selectivity, 
high atom efficiency, elimination of hazardous reagents, and easy separation 
with recovery and reuse of reagents. As a result, volatile organic solvents are 
being replaced by non-toxic, nonvolatile media such as ionic liquids, 
polyethylene glycol, and water. Alternatively, the reactions are carried out 
under solvent-free conditions. The phenomenal response, as evident from the 
growing number of publications, in order to achieve this goal is overwhelming. 
It is more advantageous to carry out reactions under solvent-free conditions 
[13]. Particularly, in recent years, reactions under solvent-free conditions have 
continuously attracted the attention of researchers both from academia and 
industry. This is due to the fact that without solvent, reactions usually need 
shorter reaction time, simpler reactors, and require simple and efficient 
workup procedures. 
Multicomponent reactions, on the other hand, have become very 
popular in the discovery of biologically active novel compounds due to its 
simple experimentation, atom economy and high yields of the products [14]. 2-
Amino-4H-pyran derivatives represent an important class of compounds. They 
are often used in cosmetics and pigments, and utilized as potentially 
biodegradable agrochemicals [15-17]. Polyfunctionalized 4H-pyrans also 
constitute a structural unit of many natural products [18,19] and biologically 
interesting compounds which possess various pharmacological activities [20] 
such as antiallergic [16], antitumor [21], antibacterial [22-26]. 4H-Pyran derivatives 
are also potential calcium channel antagonists [27] which are structurally 
similar to biologically active 1, 4-dihydropyridines. 
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4.2  Reported Synthetic Strategies 
4.2.1  Synthesis of aminochromenes 
A four component Knoevenagel-Michael addition-cyclization sequence 
has been studied for the synthesis of dihydropyranopyrazole derivatives from 
hydrazine hydrate, a malonitrile, a β-ketoester, and an aldehyde or a ketone. 
The reaction was described under catalyst- and solvent-free conditions [28] 
and using piperidine in ultrapure aqueous media [29], both at room 
temperature. But this methodology was intensively developed by Shestopalov 
and co-workers since they used a wide range of aldehydes, ketones, and β-
ketoesters to form a series of these fused heterocyclic skeletons, even if 
substituted  hydrazines  were  unreactive in this protocol [30]. 
H2N NH2
+
Me OEt
O O
N N
H
Me
O
O
CN
NH2
Scheme 4.1
CN
CN
30 °C, 5-10 min.
+
CHO
OH
R
NHN
H2O
Me OH
R
O
CN
NH
R
 
More recently, an adaptation of this four-component transformation in 
water was proposed as a green combinatorial synthesis of novel 
aminochromene derivatives bearing an hydroxymethyl pyrazole functional 
group in the four-position, instead of a fused skeleton. In this unexpected 
transformation, 2-hydroxybenzaldhyde plays a crucial role by reacting 
selectively with malonitrile to form the chromene intermediate (Scheme 4.1) 
[31]. 
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4.2.2  Solvent-free multi-component synthesis of pyranopyrazoles 
The conventional synthesis of 2-amino-3-cyano-4H-pyrans use organic 
solvent, but these solvents make the workup procedure complicated and lead 
to poor yields of products [32-36]. In recent years, 2-amino-3-cyano-4H-pyrans 
have also been synthesized under microwave [37-40], with ultrasound irradiation 
[41], or in aqueous media [42-46]. Some two-component [47] and three-component 
[48] condensations have been introduced for the synthesis of 2-amino-3-cyano-
4H-pyrans. Each of these methods has its own merit, with at least one of the 
limitations of low yields, long reaction time, effluent pollution, harsh reaction 
conditions, and tedious workup procedures. All of these reasons spur us to 
study the possibility of synthesis of 2-amino-3-cycano-4-aryl-7,7-dimethyl-
5,6,7,8-tetrahydrobenzo[b]pyrans and 6-amino-5-cyano-4-aryl-1,4-dihydro-
pyrano[2,3-c]pyrazoles under solvent-free conditions.  
 
Li et al. [49] report a highly efficient procedure for the synthesis of 2-
amino-3-cycano-4-aryl-7,7-dimethyl-5,6,7,8-tetrahydrobenzo[b]pyrans and 6-
amino-5-cyano -4-aryl-1,4-dihydropyrano[2,3-c]pyrazoles via a one-pot 
grinding method under solvent-free conditions using an inexpensive and 
commercially available D,L-proline as catalyst (Schemes 4.2 and 4.3). 
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In a typical general experimental procedure, aromatic aldehydes, 
malononitrile, dimedone [1,3-cyclohexanedione or 3-methyl-1-phenyl-2-
pyrazolin-5-one], and a catalytic amount of D,L-proline are added to a mortar. 
The mixture is ground by mortar and pestle at room temperature for a period. 
The solid product is obtained from an intermediate melt and then it is laid up 
at room temperature for 30 min. The mixture is transferred to ice water and 
then filtered off. The crude products are purified by recrystallization by ethanol 
to afford the products in good yields. 
 
A simple, green and efficient protocol is developed with per-6-amino-b-
cyclodextrin (per-6-ABCD) which acts simultaneously as a supra-molecular 
host and as an efficient solid base catalyst for the solvent-free syntheses of 
various dihydropyrano[2,3-c]pyrazole derivatives involving a four-component 
reaction (Scheme 4.4). 
 Per-6-amino-b-cyclodextrin (per-6-ABCD) is used extensively as a 
supra-molecular chiral host and as a base catalyst for Cu-catalyzed N-
arylation [50] and for Michael addition of nitromethane to chalcones [51]. 
Kanagaraj and Pitchumani [52] have utilized per-6-ABCD as an excellent 
supramolecular host for the synthesis of pyranopyrazole derivatives, in an 
efficient and eco-friendly four-component reaction protocol under solvent free 
conditions at room temperature. It is also interesting to note that the catalyst 
can be recovered and reused several times. 
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4.2.3  Syntheses of polyfunctionalized phenols linked to heterocycles 
Boghdadie et al. [53] reported that, a solution of 4-(hydroxyl-3-
methoxybenzylidine) malononitrile and 3-ethyl-1-phenyl-2-pyrazolin-5-one, in 
ethanol (50 ml) and two drops of piperidine was heated under reflux for 2 
hours, cooled and poured onto water. The products were recrystallized from 
ethanol to give the corresponding compound 6-amino-3-ethyl-4-(4-hydroxy-3-
methoxyphenyl)-1-phenyl-4H-pyrano[3,2-d]pyrazole-5-carbonitrile (scheme 
4.5). 
 
4.2.4  Benzopyran derivatives 
4.2.4.1 4H-benzo[b]pyrans using TBAB as a catalyst 
Fard et al. [54] reported a highly efficient procedure for the preparation 
of 4H-benzo[b]pyrans and pyrano[2,3-d]pyrimidinones via a domino 
Knoevenagelcyclo-condensation reaction using TBAB as a catalyst in water. 
In a typical experimental procedure, a mixture of aromatic aldehyde, 
malononitrile, dimedone or barbituric acid in water under reflux condition, was 
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stirred in the presence of a catalytic amount of TBAB (10 mol%) to afford the 
4H-benzo[b]pyrans and pyrano[2,3- d]pyrimidinones (Scheme 4.6). 
 
4.2.4.2  Benzopyran using uncatalyzed aqueous media. 
In aqueous media uncatalyzed reaction of o-hydroxy benzaldehyde 
with malenonitrial or ethylcyanoacetate, the first formed Knoevenagel 
condensation products underwent cyclization as a result of nucleophilic attack 
by the hydroxyl group on the cyano group. Thus 2-amino-2H-1-benzopyrane-
3-carbonitriale or carboxylate were formed in excellent yields shown in 
scheme 4.7[55]. 
Scheme 4.7
CHO
OH
+
R'
CN
H2O
R.T. Stirring O NH2
R'
R'=CN, COOEt
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4.2.4.3  2-Amino-3-cyanochromene using MgO as a catalyst 
Kumar et al. [56] have reported an environmentally benign synthetic 
process using Magnesium oxide as the catalyst and by process of grinding 
(Scheme 4.8). This is the classical reaction where in a benzaldehyde or 
ketone has first been reacted with a malanonitrile which has got an active 
hydrogen site, yielding the benzylidene malanonitrile which when reacted to a 
1,3-Diketo compound herein a meldurms acid afforded the 2-Amino-3-
cyanochromene derivative the only difference than the classical methodology 
is that the reaction has been carried at room temperature and it is grinded 
which means there are absolutely no solvent which makes it a green process 
and which is also faster and gives a higher yield. 
 
4.2.4.4  Benzopyrans using chitosan as a catalyst 
Similarly, Al-Matar et al. [57] have synthesized many compounds of this 
class using  chitosan as the catalyst (Scheme 4.9). 
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4.2.4.5    Benzopyrans using organic base as a catalyst 
More so ever Al-Matar et al. [57] have also studied the formation of the 
exact product i.e. 2-Amino-3-cyano-7-hydroxy-4H-chromene instead of 5-
hydroxy derivative when resorcinol is reacted with malanonitrile using 
piperidine and ethanol. They have come out with this result using the Nuclear 
Overhauser Effect calculation from the proton NMR spectrum. The reaction 
scheme is shown in Scheme 4.10. 
 
A variation of the Hantzsch reaction for the synthesis of 4H-pyran 
analogues of 1,4-dihydropyridines has been proposed at Bayer A.G. [58] 1,3-
Cyclohexanedione was condensed with an aldehyde and a nitrile bearing an 
activated methylene group in the presence of a catalytic amount of piperidine 
shown in Scheme 4.11 [59]. 
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They have synthesized the spiro-compounds using the cyclic ketones 
to produce the desired results but failed to obtain the chromenes when the 
aryl ketones were used in the reaction. The reaction schemes followed are 
shown in Scheme 4.12. 
 
Substituted 4,5-dihydropyrano[4,3-b]pyrans was synthesized by the 
three component reaction mixture of 4-hydroxy-6-methyl-2H-pyran-2-one, 
substituted aldehyde and nitrile bearing an activated methylene group  in the 
presence of a catalytic amount of triethylamine shown in scheme- 4.13[60]. 
Scheme 4.13
O
O
H3C OH
+
RCHO
Z
CN
NEt3 O
O
H3C O
R
Z
NH2
Z=CN, COOEt
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4.2.4.6   Benzopyrans using potassium carbonate as a catalyst 
Kidwai et al. [61] has prepared the same class of the compounds using 
water as a solvent and potassium carbonate as the required base catalyst 
(Scheme 4.14).  
Scheme 4.14
CHO +
CN
CN
HO OH O
CN
NH2HO
 
  Such compounds were prepared using different starting materials as 
diverse kinds of aldehydes viz. Phenyl, Quinolyl, Indolyl and alkyl were 
reacted with malanonitrile in presence of saturated potassium carbonate 
solution and then microwave irradiation was induced upon the reaction 
mixture which afforded the 2-Amino-3-cyano-4-substituted phenyl-7-hydroxy-
4H-chromene dervatives.  
4.2.4.7   Ionic liquids as catalyst for the synthesis of benzopyrans  
The synthesis of 4H-benzo[b]pyran derivatives has also been proposed 
by means of a basic ionic liquid-catalyzed three-component approach 
involving malononitrile, aromatic aldehydes and dimedone. The conventional 
method, requiring the use of refluxing DMF or acetic acid, lead to low yields 
and renders the isolation step troublesome. Other procedures have been 
described but all of them suffer at least from one limitation. Alternatively, it has 
been found that a small amount of N,N-dimethylaminoethylbenzyl-
dimethylammonium chloride catalyzed a rapid and high yielding solvent-free 
transformation at 60 °C with a wide variation of the aldehyde partner (Scheme 
4.15) [62]. 
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  While, Peng and Song conducted this MCR in a mixture of catalytically 
active ionic liquid and water [63], and Lingaiah and co-workers reported the use 
of a heterogeneous strong basic Mg/La mixed oxide catalyst in methanol [64]. 
Compared to the utilization of more classical solvents and organic bases, 
these strategies combine advantages in efficiency such as shorter reaction 
times and higher yields, with ecological advantages in terms of recovery and 
reusability of the catalyst. 
Scheme 4.16
Ar H
O + Z
CN
MeMe
OO
(20 mol%)
H2O, rt O
Z
NH2
ArO
Me Me
Z=CN, COOEt
[bmlm]OH
 
  This approach has been extended to cyclic 1,3-dicarbonyls for the 
synthesis of tetrahydrobenzopyrane derivatives, also known as 
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tetrahydrochromenes, which have attracted much attention due to their wide 
range of biological properties. Thus, a mixture of an aromatic aldehyde, 
dimedone, and nitrile bearing an activated methylene group in aqueous media 
catalyzed 1-butyl-3-methyl imidazolium hydroxide [65] gave the bicyclic 
heterocycle in excellent yields (Scheme 4.16). 
4.2.5   Pyranopyrazoles by using heteropolyacid as a catalyst 
Heravi et al. [66] reported facile method for the synthesis of 1,4-
dihydropyrano[2,3-c] pyrazole derivatives via three-component one-pot 
condensation of 1H-pyrazol, aldehydes and malononitrile in the presence of a 
catalytic amount of preyssler type heteropolyacid as a green and reusable 
catalyst in water or ethanol under refluxing conditions (Scheme 4.17). 
There has been considerable interest in the use of heteropolyacids as 
environmentally benign catalysts due to their unique properties such as high 
thermal stability, low cost, ease of preparation and recyclability. Numerous 
chemical reactions can occur in the presence of heteropolyacids [67]. Preyssler 
type heteropolyacid, H14[NaP5W30O110], is remarkable owing to its exclusive 
physicochemical properties. These include strong Bronsted acidity, reversible 
transformations, solubility in polar and non-polar solvents, high hydrolytic and 
thermal stability, which are all essential in catalytic processes. Preyssler 
polyanion, as a large anion, can provide many ‘‘sites’’ on the oval-shaped 
molecule that are likely to render the catalyst effective [68]. This 
heteropolyanion with [69] acidic protons, is an efficient ‘‘supper acid’’ solid 
catalyst which can be used both in the homogeneous and heterogeneous 
phases [70]. 
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4.2.6  Dihydropyrazolopyrans from 1H-indole-2,3-dione 
Aly H. Atta [71] reported the synthesis of a new series of compounds 
containing both the moieties which would result  in the formation of some 
interesting bioactive compounds. The one-pot reaction of 1H-indole-2,3-dione, 
3-methyl-1-phenyl-2-pyrazolin-5-one, and active methylenes, namely 
malononitrile, ethyl cyanoacetate, pyrazolone, and acetyl acetone afforded the 
products. These products can be obtained via reaction of 3-[3-methyl-5-oxo-1-
phenyl-1,5-dihydro-pyrazol-(4Z)-ylidene]-1,3-dihydro-indol-2-one with the 
corresponding active methylenes (Scheme 4.18). 
 
4.2.7  Synthesis of spiro-dihydropyrazolo[3,4-b]pyrans 
Evans et al. [72] described a three-component condensation in which 
substituted piperidin-4-ones have been used in place of aromatic aldehydes to 
synthesize a new spiro heterocyclic system. They report that the base-
catalyzed reaction of substituted piperidin-4-ones, pyrazol-5-ones, and 
malononitrile  proceeds in ethanol at 20 °C with the formation of substituted 6-
amino-5-cyanospiro-4-(piperidine-4’)-2H,4H-dihydropyrazolopyrans (Scheme 
4.19). 
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Scheme 4.19
N
O
R1
N
HN
O
R2
+
CH2(CN)2 O
HN
N
N
R2
R1
CN
NH2
R1 = CH3, CH3CO, COOEt
R2 = CH3, CH3OCH2, CH3CH2CH2
 
Three-component condensation of 4-piperidinones, 5-pyrazolones, and 
malononitrile proceeds chemically and electrochemically and is a convenient 
one-step means of synthesis of substituted 6-amino-5-cyanospiro-4-
(piperidine-4’)-2H,4H-dihydropyrazolo[3,4-b]pyrans. The electrochemical 
reactions proceed under milder conditions and with yields 12-15% greater 
than those of the reactions catalyzed by chemical bases. 
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4.3    Present Work 
Pyran and fused pyran derivatives have attracted a great deal of 
interest due to their association with various kinds of biological properties. 
They have been reported for their antimicrobial [73-76], antiviral [77, 78], 
anticonvulsant [79], cytotoxic [80] and antigenotoxic [81] activities. The 
incorporation of another heterocyclic moiety in pyrans either in the form of a 
substituent or as a fused component changes its properties and converts it 
into an altogether new and important heterocyclic derivative.  
2-Amino-chromenes represent an important class of compounds being 
the main components of many naturally occurring products and are widely 
employed as cosmetics, pigments, [82, 83] and potential biodegradable 
agrochemicals [84]. Fused chromenes are biologically active compounds with a 
wide spectrum of activities viz. mutagenicity,[85] antiproliferative, [86] sex 
pheromone,[87] antitumor,[88] and central nervous system activity [89]. 
 
Kemnitzer, W. & Cio Kai et.al. discovered a new series of 4-Aryl-
4Hchromene as Apoptosis inducers using a cell and caspase based high 
throughput screening assay [90].  
 
The detailed literature survey on this class of compounds with 2-
Amino-4-substitutedphenyl-3-carboxylate derivatives have not been explored 
and hence synthetic work on this chemical entity was initiated and evaluated 
for its biological activity. 
 
We report herein the synthesis of substituted 2-Amino-4H-chromene 
(KMK-301 to KMK-320), a scaffold from which a diverse range of other 
biologically important New Chemical Entities (NCE’s) could be generated. 
 
 
 
 
 
Chapter 4                                                                                         Benzopyran 
 
Page 176 
 
4.4  Reaction Scheme 
O
CH3
HO NH2
X
CH3
OHHO
+
CN
X
K2CO3
Ethanol
R
R
X = CN, COOEt
 
 
4.4.1 Physical Data Table 
Code X R M.F. 
M.W. 
(gm/ 
mole) 
M.P. 
(0C) 
% of 
yield 
 
KMK-301 CN H C17H14N2O2 278 205-207 60 
KMK-302 CN  4-OCH3 C18H16N2O3 308 210-212 70 
KMK-303 CN  2-OCH3 C18H16N2O3 308 198-200 65 
KMK-304 CN  4-NO2 C17H13N3O4 323 172-174 66 
KMK-305 CN  2-NO2 C17H13N3O4 323 158-160 61
KMK-306 CN  4-CH3 C18H16N2O2 292 170-172 72 
KMK-307 CN  4-Br C17H13BrN2O2 356 148-150 78 
KMK-308 CN  3-Br C17H13BrN2O2 356 160-162 75 
KMK-309 CN  4-Cl C17H13ClN2O2 312 194-196 77 
KMK-310 CN  3-Cl C17H13ClN2O2 312 178-180 80 
KMK-311 COOEt H C19H19NO4 325 180-182 56 
KMK-312 COOEt  4-OCH3 C20H21NO5 355 166-168 60 
KMK-313 COOEt  2-OCH3 C20H21NO5 355 174-176 58 
KMK-314 COOEt  4-NO2 C19H18N2O6 370 148-150 65 
KMK-315 COOEt  2-NO2 C19H18N2O6 370 142-144 55 
KMK-316 COOEt  4-CH3 C20H21NO4 339 192-194 68 
KMK-317 COOEt  4-Br C19H18BrNO4 403 200-202 70 
KMK-318 COOEt  3-Br C19H18BrNO4 403 174-176 75 
KMK-319 COOEt  4-Cl C19H18ClNO4 359 176-178 72 
KMK-320 COOEt  3-Cl C19H18ClNO4 359 130-132 78 
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4.4.2  Reaction Mechanism 
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4.5  Experimental 
4.5.1  Materials and Methods 
Melting points were determined in open capillary tubes and are 
uncorrected. Formation of the compounds was routinely checked by TLC on 
silica gel-G plates of 0.5 mm thickness and spots were located by iodine. IR 
spectra were recorded on Shimadzu FT-IR-8400 instrument using KBr pellet 
method. Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model 
using Direct Injection Probe technique. 1H NMR was determined in DMSO-d6 
solution on a Bruker Ac 400 MHz spectrometer. Elemental analysis of all the 
synthesized compounds was carried out on Elemental Vario EL III Carlo Erba 
1108 model and the results are in agreements with the structures assigned. 
 
4.5.2 Synthesis of 2-(Substitutedbenzylidene) malononitrile. 
The product 2-(Substitutedbenzylidene) malononitrile has been 
synthesized by the reaction of different substituted aldehyde and malononitrial 
in presence of base (pipyridine). [91] 
 
4.5.3 General method for the Synthesis of 2-amino-7-hydroxy-5-methyl-
4-(substitutedphenyl)-4H-chromene-3-carbonitrile.(KMK 301-310) 
 0.01 mole of 2-(Substitutedbenzylidene) malononitrile and 0.01 mole of 
5-methyl resorcinol dissolve in absolute ethanol. Stirring the reaction mixture 
at room temperature, gradually added the anhydrous potassium carbonate 
and stirring the reaction mixture at room temperature for 5-6 hours. After 
completion of reaction, pour the reaction mixture in dilute hydrochloric acid 
and neutralized it, separated the solid product filter, dry and crystallized from 
ethanol.     
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4.5.3.1 2-amino-7-hydroxy-5-methyl-4-phenyl-4H-cromene-3-
carbonitrile (KMK-301) 
Yield: 60%;  MP: 205-2070C;  MS: m/z 278;  
Elemental Analysis for C17H14N2O2:   
Calculated: C, 73.37; H, 5.07; N, 10.07; %.  
Found: C, 73.27; H, 5.0; N, 10.01; %. 
 
4.5.3.2 2-amino-7-hydroxy-4-(4-methoxyphenyl)-5-methyl-4H-
cromene-3-carbonitrile (KMK-302) 
Yield: 70%;  MP: 210-2120C;  MS: m/z 308;  
Elemental Analysis for C18H16N2O3:   
Calculated: C, 70.12; H, 5.23; N, 9.09; %. 
Found: C, 70.10; H, 5.21; N, 9.0; %. 
 
 
4.5.3.3 2-amino-7-hydroxy-4-(2-methoxyphenyl)-5-methyl-4H-
cromene-3-carbonitrile(KMK-303) 
Yield: 65%;  MP: 198-2000C;  MS: m/z 308;  
Elemental Analysis for C18H16N2O3:   
Calculated: C, 70.12; H, 5.23; N, 9.09; %.  
Found: C, 70.02; H, 5.20; N, 9.05;%. 
 
4.5.3.4 2-amino-7-hydroxy-5-methyl-4-(4-nitrophenyl)-4H-cromene-
3-carbonitrile (KMK-304) 
Yield: 66%;  MP: 172-1740C;  MS: m/z 323;  
Elemental Analysis for C17H13N3O4:   
Calculated: C, 63.16; H, 4.05; N, 13.00; %.  
Found: C, 63.11; H, 4.0; N, 12.80; %. 
 
 
 
 
 
Chapter 4                                                                                         Benzopyran 
 
Page 180 
 
4.5.3.5 2-amino-7-hydroxy-5-methyl-4-(2-nitrophenyl)-4H-cromene-
3-carbonitrile (KMK-305) 
Yield: 61%;  MP: 158-1600C;  MS: m/z 323;  
Elemental Analysis for C17H13N3O4:   
Calculated: C, 63.16; H, 4.05; N, 13.00; %. 
Found: C, 63.12; H, 3.95; N, 12.90; %. 
 
4.5.3.6 2-amino-7-hydroxy-5-methyl-4-(p-tolyl)-4H-cromene-3-
carbonitrile (KMK-306) 
Yield: 72%;  MP: 170-1720C;  MS: m/z 292;  
Elemental Analysis for C18H16N2O2:   
Calculated: C, 73.95; H, 5.52; N, 9.58; %.  
Found: C, 73.75; H, 5.50; N, 9.50; %. 
 
 
4.5.3.7 2-amino-4-(4-bromophenyl)-7-hydroxy-5-methyl-4H-
cromene-3-carbonitrile (KMK-307) 
Yield: 78%;  MP: 148-1500C;  MS: m/z 356;  
Elemental Analysis for C17H13BrN2O2:   
Calculated: C, 57.16; H, 3.67; N, 7.84; %. 
Found: C, 57.08; H, 3.65; N, 7.81; %. 
 
 
4.5.3.8 2-amino-4-(3-bromophenyl)-7-hydroxy-5-methyl-4H-
cromene-3-carbonitrile(KMK-308) 
Yield: 75%;  MP: 160-1620C;  MS: m/z 356;  
Elemental Analysis for C17H13BrN2O2:   
Calculated: C, 57.16; H, 3.67; N, 7.84; %.  
Found: C, 57.14; H, 3.61; N, 7.83; %. 
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4.5.3.9 2-amino-4-(4-chlorophenyl)-7-hydroxy-5-methyl-4H-
cromene-3-carbonitrile (KMK-309) 
Yield: 77%;  MP: 194-1960C;  MS: m/z 312;  
Elemental Analysis for C17H13ClN2O2:   
Calculated: C, 65.29; H, 4.19; N, 8.96; %.  
Found: C, 65.27; H, 4.11; N, 8.95; %. 
 
 
4.5.3.10 2-amino-4-(3-chlorophenyl)-7-hydroxy-5-methyl-4H-
cromene-3-carbonitrile (KMK-310) 
Yield: 80%;  MP: 178-1800C;  MS: m/z 312;  
Elemental Analysis for C17H13ClN2O2:   
Calculated: C, 65.29; H, 4.19; N, 8.96; %. 
Found: C, 65.09; H, 4.15; N, 8.88; %. 
 
 
 
 
4.5.4 Synthesis of Ethyl-2-cyano-3-Substitutedphenylacrylate. 
The product Ethyl-2-cyano-3-Substitutedphenylacrylate has been 
synthesized by the reaction of different substituted aldehyde and ethyl cyano 
acetate in presence of base (pipyridine). [91] 
4.5.5 General method for the Synthesis of Ethyl-2-amino-7-hydroxy-5-
methyl-4-(substitutedphenyl)-4H-chromene-3-carboxylate.(KMK 311-320) 
 0.01 mole of Ethyl-2-cyano-3-Substitutedphenylacrylate and 0.01 mole 
of 5-methyl resorcinol dissolve in absolute ethanol. Stirring the reaction 
mixture at room temperature, gradually added the anhydrous potassium 
carbonate and stirring the reaction mixture at room temperature for 8-10 
hours. After completion of reaction, pour the reaction mixture in dilute 
hydrochloric acid and neutralized it, separated the solid product filter, dry and 
crystallized from ethanol.     
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4.5.5.1 Ethyl-2-amino-7-hydroxy-5-methyl-4-phenyl-4H-chromene-3-
carboxylate(KMK-311) 
Yield: 56%;  MP: 180-1820C;  MS: m/z 325;  
Elemental Analysis for C19H19NO4:   
Calculated: C, 70.14; H, 5.89; N, 4.31; %.  
Found: C, 70.16; H, 5.80; N, 4.25; %. 
 
4.5.5.2 Ethyl-2-amino-7-hydroxy-4-(4-methoxyphenyl)-5-methyl-4H-
chromene-3-carboxylate(KMK-312) 
Yield: 60%;  MP: 166-1680C;  MS: m/z 355;  
Elemental Analysis for C20H21NO5:   
Calculated: C, 67.59; H, 5.96; N, 3.94; %.  
Found: C, 67.54; H, 5.96; N, 3.91; %. 
 
4.5.5.3 Ethyl-2-amino-7-hydroxy-4-(2-methoxyphenyl)-5-methyl-4H-
chromene-3-carboxylate(KMK-313) 
Yield: 58%;  MP: 174-1760C;      MS:m/z 355;  
Elemental Analysis for C20H21NO5:   
Calculated: C, 67.59; H, 5.96; N, 3.94; %. 
Found: C, 67.58; H, 5.93; N, 3.90; %. 
 
4.5.5.4 Ethyl-2-amino-7-hydroxy-5-methyl-4-(4-nitrophenyl)-4H-
chromene-3-carboxylate(KMK-314) 
Yield: 65%;  MP: 148-1500C;     MS:m/z 370;  
Elemental Analysis for C19H18N2O6:   
Calculated: C, 61.62; H, 4.90; N, 7.56; %. 
Found: C, 61.61; H, 4.95; N, 7.51; %. 
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4.5.5.5 Ethyl-2-amino-7-hydroxy-5-methyl-4-(2-nitrophenyl)-4H-
chromene-3-carboxylate(KMK-315) 
Yield: 55%;  MP: 142-1440C;     MS: m/z 370;  
Elemental Analysis for C19H18N2O6:   
Calculated: C, 61.62; H, 4.90; N, 7.56; %.  
Found: C, 61.60; H, 4.85; N, 7.50; %. 
 
4.5.5.6 Ethyl-2-amino-7-hydroxy-5-methyl-4-(p-tolyl)-4H-chromene-
3-carboxylate(KMK-316) 
Yield: 68%;  MP: 192-1940C;   MS: m/z 
339;  
Elemental Analysis for C20H21NO4:   
Calculated: C, 70.78; H, 6.24; N, 4.13; %.  
Found: C, 70.72; H, 6.21; N, 4.11; %. 
 
 
4.5.5.7 Ethyl-2-amino-4-(4-bromophenyl)-7-hydroxy-5-methyl-4H-
chromene-3-carboxylate(KMK-317) 
Yield: 70%;  MP: 200-2020C;    MS: m/z 403;  
Elemental Analysis for C19H18BrNO4:   
Calculated: C, 56.45; H, 4.49; N, 3.46; %.  
Found: C, 56.36; H, 4.48; N, 3.40; %. 
 
 
4.5.5.8 Ethyl-2-amino-4-(3-bromophenyl)-7-hydroxy-5-methyl-4H-
chromene-3-carboxylate(KMK-318) 
Yield: 75%;  MP: 174-1760C;      MS: m/z 403;  
Elemental Analysis for C19H18BrNO4:   
Calculated: C, 56.45; H, 4.49; N, 3.46; %.  
Found: C, 56.41; H, 4.48; N, 3.40; %. 
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4.5.5.9 Ethyl-2-amino-4-(4-chlorophenyl)-7-hydroxy-5-methyl-4H-
chromene-3-carboxylate(KMK-319) 
Yield: 72%;  MP: 176-1780C;     MS: m/z 359;  
Elemental Analysis for C19H18ClNO4:   
Calculated: C, 63.42; H, 5.04; N, 3.89; %. 
Found: C, 63.41; H, 5.0; N, 3.80; %. 
 
 
4.5.5.10 Ethyl-2-amino-4-(3-chlorophenyl)-7-hydroxy-5-methyl-4H-
chromene-3-carboxylate(KMK-320) 
Yield: 78%;  MP: 130-1320C;      MS: m/z 359;  
Elemental Analysis for C19H18ClNO4:   
Calculated: C, 63.42; H, 5.04; N, 3.89; %.  
Found: C, 63.38; H, 5.01; N, 3.80; %. 
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4.6  Spectral Discussion 
4.6.1  IR Spectral Study 
IR spectra were recorded on Shimadzu FT-IR-8400 model using KBr 
pellet method. Various functional groups present in molecule were identified 
by characteristic frequency obtained for them. For 2-amino benzopyran (KMK-
301 to 320), confirmatory bands for primary amine (-NH2) and free hydroxyl (-
OH) stretching band was observed at 3250-3500 cm-1, carbonyl of ester and 
cyanide stretching band was observed at 1630-1700 cm-1 and 2200-2230 cm-1 
respectively. Another characteristic band for N-H deformation and C-N 
stretching were observed at 1500-1600 cm-1 and 1200-1360 cm-1 respectively. 
4.6.2  1H NMR Spectral Study 
1H NMR spectra were recorded in DMSO-d6 solution on a Bruker Ac 
400 MHz spectrometer using TMS as an internal standard. Number of protons 
and their chemical shifts were found to support the structure of the 
synthesized compounds. 
1H NMR spectra confirmed the structures of 2-amino benzopyran 
(KMK-301 to 320) on the basis of following signals: singlet for primary amino 
group proton was observed at 6.50-7.50 δ ppm and free phenol –OH group 
proton was observed at 9.30-9.60 δ ppm. The aromatic ring protons and J 
value were found to be in accordance with substitution pattern on phenyl ring.  
4.6.3  Mass Spectral Study 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model 
using Direct Injection Probe technique. Systematic fragmentation pattern was 
observed in mass spectral analysis. Molecular ion peak was observed in 
agreement with molecular weight of respective compound. Mass 
fragmentation pattern for a representative compound of each series is 
depicted below. 
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IR spectra of KMK-302 
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Sr. No. Frequency (cm-1) Vibration Mode 
1 3441 O-H Streching of primary alcohol 
2 3337 N-H Streching of primary amine 
3 3048 C-H Streching of aromatic ring 
4 2963 C-H Streching of CH3 group 
5 2180 C≡N Streching of nitrial group 
6 1648 N-H deformation of NH2 group 
7 1505-1408 O-H in plane bending 
8 1296 C-N Streching of carbon bonded to amine 
9 1138 C-O-C symmetrical stretching for ethers  
10 1068 C-H in plane bending of phenyl ring 
11 836 out of plane bending for disubstituted aromatic ring 
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1H-NMR spectra of KMK-302 
 
 
Signal 
No. 
 
 
Signal Position 
δppm 
 
 
Relative No. 
of Protons 
 
 
Multiplicity 
 
 
Inference 
 
1 1.89 3 Singlet -CH3(a) 
2 3.7 3 Singlet -OCH3(b) 
3 4.46 1 Singlet -H(c) 
4 6.32 1 Singlet Ar-H(d) 
5 6.37 1 Singlet Ar-H(e) 
6 6.72 2 Singlet -NH2(f) 
7 6.82-6.84 2 Doublet Ar-H(g,g’) 
8 6.93-6.96 2 Doublet Ar-H(h,h’) 
9 9.59 1 Singlet -OH(i) 
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Expanded 1H-NMR spectra of KMK-302 
 
 
Mass spectra of KMK-302 
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Mass fragmentation pattern for KMK-302 
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IR spectra of KMK-312 
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1 3414 O-H Streching of primary alcohol 
2 3298 N-H Streching of primary amine 
3 2972 C-H Streching of aromatic ring 
4 1660 C=O Streching frequency of ester 
5 1618 N-H deformation of NH2 group 
6 1512 O-H in plane bending 
7 1462 C=C Steching of aromatic ring 
8 1311 C-N Streching of carbon bonded to amine 
9 1245 C-O-C asymmetrical stretching for ethers 
10 1145 C-O-C symmetrical stretching OCH3 group 
11 1069 C-H in plane bending of phenyl ring 
12 842 Out of plane bending for disubstituted aromatic ring 
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1H-NMR spectra of KMK-312 
 
 
Signal 
No. 
 
 
Signal Position 
δppm 
 
 
Relative No. 
of Protons 
 
 
Multiplicity 
 
 
Inference 
 
1 1.17-1.22 3 Triplet -CH2CH3(a) 
2 1.99 3 Singlet -CH3(b) 
3 3.66 3 Singlet -OCH3(c) 
4 3.99-4.04 2 Quartet -CH2(d)CH3 
5 4.70 1 Singlet -H(e) 
6 6.35 2 Singlet Ar-H(f,f’) 
7 6.74-6.76 2 Doublet Ar-H(g,g’) 
8 6.97-6.99 2 Doublet Ar-H(h,h’) 
9 7.44 2 Singlet -NH2(i) 
10 9.49 1 Singlet -OH(j) 
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Expanded 1H-NMR spectra of KMK-312 
 
Mass spectra of KMK-312 
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Mass fragmentation pattern for KMK-312 
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4.7  Biological Evaluation 
4.7.1  Antimicrobial Evaluation 
All the synthesized compounds (KMK-301 to KMK-320) were tested 
for their antibacterial and antifungal activity (MIC) in vitro by broth dilution 
method [92, 93] with two Gram-positive bacteria Staphylococcus aureus MTCC-
96, Streptococcus pyogenes MTCC 443, two Gram-negative bacteria 
Escherichia coli MTCC 442, Pseudomonas aeruginosa MTCC 441 and three 
fungal strains Candida albicans MTCC 227, Aspergillus Niger MTCC 282, 
Aspergillus clavatus MTCC 1323 taking ampicillin, chloramphenicol, 
ciprofloxacin, norfloxacin, nystatin, and greseofulvin as standard drugs. The 
standard strains were procured from the Microbial Type Culture Collection 
(MTCC) and Gene Bank, Institute of Microbial Technology, Chandigarh, India.  
 The minimal inhibitory concentration (MIC) values for all the newly 
synthesized compounds, defined as the lowest concentration of the 
compound preventing the visible growth, were determined by using micro 
dilution broth method according to NCCLS standards [92]. Serial dilutions of 
the test compounds and reference drugs were prepared in Muellere-Hinton 
agar. Drugs (10 mg) were dissolved in dimethylsulfoxide (DMSO, 1 mL). 
Further progressive dilutions with melted Muellere-Hinton agar were 
performed to obtain the required concentrations. In primary screening 1000 μg 
mL-1, 500 μg mL-1 and 250 μg mL-1 concentrations of the synthesized drugs 
were taken. The active synthesized drugs found in this primary screening 
were further tested in a second set of dilution at 200 μg mL-1, 100 μg mL-1, 50 
μg mL-1, 25 μg mL-1, 12.5 μg mL-1, and 6.25 μg mL-1 concentration against all 
microorganisms. The tubes were inoculated with 108 cfu mL-1 (colony forming 
unit/mL) and incubated at 37 ºC for 24 h. The MIC was the lowest 
concentration of the tested compound that yields no visible growth (turbidity) 
on the plate. To ensure that the solvent had no effect on the bacterial growth, 
a control was performed with the test medium supplemented with DMSO at 
the same dilutions as used in the experiments and it was observed that 
DMSO had no effect on the microorganisms in the concentrations studied. 
Chapter 4                                                                                         Benzopyran 
 
Page 195 
 
Antibacterial and antifungal activity of synthesized compounds KMK-
301 to 320 
Code 
Antibacterial Activity Antifungal Activity 
Minimal Bactericidal 
Concentration μg/ml Minimal Fungicidal 
Concentration μg/ml Gram +ve 
Bacteria 
Gram –ve 
Bacteria 
S.a. S.p. E.c. P.a. C.a. A.n. A.c. 
KMK-301 200 100 100 100 250 1000 250 
KMK-302 200 500 62.5 500 1000 500 500 
KMK-303 100 200 500 500 250 >1000 >1000 
KMK-304 250 62.5 250 500 >1000 >1000 >1000 
KMK-305 500 100 100 125 500 >1000 1000 
KMK-306 100 200 62.5 125 500 >1000 >1000 
KMK-307 500 500 250 500 500 >1000 1000 
KMK-308 500 62.5 250 250 250 200 200 
KMK-309 500 500 100 250 500 500 >1000 
KMK-310 500 500 100 250 250 1000 250 
KMK-311 200 500 250 500 1000 500 >1000 
KMK-312 500 100 62.5 100 500 500 >1000 
KMK-313 250 500 500 500 200 500 200 
KMK-314 200 100 100 500 500 1000 200 
KMK-315 500 62.5 62.5 100 250 1000 1000 
KMK-316 250 250 250 250 500 500 1000 
KMK-317 250 500 500 500 250 >1000 >1000 
KMK-318 500 100 500 250 1000 >1000 1000 
KMK-319 500 500 1000 1000 500 1000 1000 
KMK-320 500 250 500 500 1000 1000 1000 
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Minimal Inhibition Concentration 
 
Standard Drugs S.aureus S.pyogenus E.coli  P.aeruginosa 
(microgramme/ml) 
Ampicillin 250 100 100 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 50 50 25 25 
Norfloxacin 10 10 10 10 
 
Minimal Fungicidal Concentration 
 
Standard Drugs C.Albicans  A.Niger  A.Clavatus 
(microgramme/ml) 
Nystatin 100 100 100 
Greseofulvin 500 100 100 
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